[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 941
1. Pakasa NM, Pasquier B, Chambonnière ML, Morrison AL, Khaddage A, Perret AG, Dumollard JM, Barral FG, Péoc'h M: Atypical presentations of solitary fibrous tumors of the central nervous system: an analysis of unusual clinicopathological and outcome patterns in three new cases with a review of the literature. Virchows Arch; 2005 Jul;447(1):81-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical presentations of solitary fibrous tumors of the central nervous system: an analysis of unusual clinicopathological and outcome patterns in three new cases with a review of the literature.
  • Central nervous system (CNS) solitary fibrous tumors (SFTs) are rare mesenchymal neoplasms recognized less than a decade ago.
  • Approximately 60 cases of SFT have been reported in the central nervous system.
  • We describe three atypical SFTs of the CNS, two intracranial and one within the spine.
  • The intraspinal tumor occurred at T5-T7 in a patient with multiple café-au-lait spots, was predominantly myxoid and developed a second similar lesion at S3-S5 14 years later.
  • The MiB 1 index was lower in the second tumor.
  • These atypical presentations gave us an opportunity to provide further information about the natural histological course of CNS SFTs.
  • [MeSH-major] Brain Neoplasms / pathology. Fibroma / pathology. Sella Turcica / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasms, Second Primary

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1999 Dec;30(12):1464-73 [10667425.001]
  • [Cites] Pathol Int. 2000 Oct;50(10):808-17 [11107053.001]
  • [Cites] Virchows Arch. 2004 May;444(5):459-64 [15014990.001]
  • [Cites] Neurosurgery. 2004 Jan;54(1):213-6; discussion 216-7 [14683560.001]
  • [Cites] J Neurosurg. 2004 Apr;100(4 Suppl Spine):358-63 [15070144.001]
  • [Cites] APMIS. 2000 Sep;108(9):617-25 [11110050.001]
  • [Cites] Histopathology. 1993 Mar;22(3):282-4 [8495961.001]
  • [Cites] J Neurosurg. 2000 Apr;92(2 Suppl):217-20 [10763696.001]
  • [Cites] Neurol Med Chir (Tokyo). 2004 May;44(5):249-54 [15200060.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Nov;131(1):69-73 [11734322.001]
  • [Cites] Pediatr Dev Pathol. 2001 May-Jun;4(3):267-75 [11370264.001]
  • [Cites] Neurosurgery. 2004 Apr;54(4):1004-9; discussion 1009 [15046670.001]
  • [Cites] J Neurosurg. 2000 Sep;93(3):490-3 [10969951.001]
  • [Cites] Am J Clin Pathol. 1996 Aug;106(2):217-24 [8712177.001]
  • [Cites] Ann Pathol. 1999 Dec;19(6):532-5 [10617813.001]
  • [Cites] Surg Neurol. 2004 Feb;61(2):174-8; discussion 178-9 [14751636.001]
  • [Cites] Neurosurgery. 1996 Jul;39(1):182-5 [8805158.001]
  • [Cites] Neuroradiology. 1981 Mar;21(2):55-65 [6259553.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1330-42 [12360048.001]
  • [Cites] Neurosurg Rev. 2004 Oct;27(4):246-51 [15138847.001]
  • [Cites] J Neurooncol. 2001 Aug;54(1):57-69 [11763424.001]
  • [Cites] Acta Neuropathol. 2001 Oct;102(4):349-54 [11603810.001]
  • [Cites] Am J Surg Pathol. 1997 Nov;21(11):1354-60 [9351573.001]
  • [Cites] Ann Diagn Pathol. 2003 Jun;7(3):169-73 [12808569.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1841-7 [10362810.001]
  • [Cites] Int J Surg Pathol. 2002 Jul;10(3):217-21 [12232579.001]
  • [Cites] Arch Pathol Lab Med. 2003 Apr;127(4):432-9 [12683870.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jun;135(2):160-4 [12127400.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):477-83 [9130996.001]
  • [Cites] J Neuroimaging. 2004 Jul;14(3):281-4 [15228772.001]
  • (PMID = 15926073.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


2. Basto D, Trovisco V, Lopes JM, Martins A, Pardal F, Soares P, Reis RM: Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathol; 2005 Feb;109(2):207-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Up-regulation of this pathway due to RAS mutations is found in approximately 30% of human tumors.
  • Gliomas are the most frequent primary central nervous system tumors and the molecular mechanisms that underlie the development and progression of these tumors are far from being completely understood.
  • The purpose of this study was to clarify the incidence of B-RAF mutations and their possible relation with tumor progression in a series of 82 human gliomas, including 49 astrocytic and 33 oligodendroglial tumors.
  • [MeSH-minor] Adult. Aged. Blotting, Northern / methods. DNA Mutational Analysis / methods. Exons. Female. Humans. Male. Middle Aged

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15791479.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


3. Liu M, Gu Y, Liu Y, Li J, He J, Lin S, Gu X: Establishment and characterization of two cell lines derived from primary cultures of Gekko japonicus cerebral cortex. Cell Biol Int; 2010 Feb;34(2):153-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adult Gekko japonicus is one of those vertebrates that are able to regenerate their missing or amputated tail.
  • The cell lines will provide a useful in vitro model for gecko neuroglial cells and facilitate systematic studies investigating the biological functions of specific gene products related to regeneration of the central nervous system.
  • [MeSH-minor] Animals. Antigens, Viral, Tumor / genetics. Antigens, Viral, Tumor / metabolism. Cell Proliferation. G0 Phase. G1 Phase. Galactosylceramides / metabolism. Glial Fibrillary Acidic Protein / metabolism. Immunohistochemistry. Karyotyping. Lizards


Advertisement
4. Bosco A, Cusato K, Nicchia GP, Frigeri A, Spray DC: A developmental switch in the expression of aquaporin-4 and Kir4.1 from horizontal to Müller cells in mouse retina. Invest Ophthalmol Vis Sci; 2005 Oct;46(10):3869-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: In adult retina, aquaporin-4 (AQP4) and inwardly rectifying K(+) (Kir4.1) channels localize to astrocyte and Müller cell membranes facing vascular and vitreous compartments, optimizing clearance of extracellular K(+) and water from the synaptic layers.
  • The finding of AQP4 in neurons is novel, since AQP4 expression within the central nervous system is restricted to glia.
  • [MeSH-minor] Animals. Animals, Newborn. Calbindins. Fluorescent Antibody Technique, Indirect. Homeodomain Proteins / metabolism. Mice. Mice, Inbred C57BL. Microscopy, Confocal. Neurofilament Proteins / metabolism. S100 Calcium Binding Protein G / metabolism. Tumor Suppressor Proteins. Water-Electrolyte Balance

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16186376.001).
  • [ISSN] 0146-0404
  • [Journal-full-title] Investigative ophthalmology & visual science
  • [ISO-abbreviation] Invest. Ophthalmol. Vis. Sci.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL07675; United States / NIMH NIH HHS / MH / MH65495; United States / NINDS NIH HHS / NS / NS41282
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aqp4 protein, mouse; 0 / Aquaporin 4; 0 / Calbindins; 0 / Eye Proteins; 0 / Homeodomain Proteins; 0 / Kcnj10 (channel); 0 / Neurofilament Proteins; 0 / Potassium Channels, Inwardly Rectifying; 0 / S100 Calcium Binding Protein G; 0 / Tumor Suppressor Proteins; 0 / prospero-related homeobox 1 protein
  •  go-up   go-down


5. Jensen J, Krakauer M, Sellebjerg F: Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b. Cytokine; 2005 Jan 7;29(1):24-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple sclerosis (MS), an inflammatory, demyelinating disease of the central nervous system (CNS), is thought to be caused by a T cell-mediated attack on CNS myelin and axons.
  • We found decreases in CD4 and CD8 T cell expression of the CD49d/VLA-4 molecule, increases in plasma concentrations of soluble vascular cell adhesion molecule (sVCAM-1), and increases in plasma concentrations of tumor necrosis factor and interleukin (IL)-12 p40 chain in patients with MS who were initiated on de novo treatment with IFN-beta1b.
  • [MeSH-minor] Adult. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Cell Adhesion. Enzyme-Linked Immunosorbent Assay. Female. Flow Cytometry. Humans. Integrin alpha1 / biosynthesis. Intercellular Adhesion Molecule-1 / blood. Interferon beta-1b. Interleukin-12 / metabolism. Interleukin-12 Subunit p40. Leukocytes, Mononuclear / metabolism. Male. Middle Aged. Protein Subunits / metabolism. Recombinant Proteins / chemistry. Tumor Necrosis Factor-alpha / metabolism. Vascular Cell Adhesion Molecule-1 / blood. Vascular Cell Adhesion Molecule-1 / metabolism

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • Hazardous Substances Data Bank. Interferon Beta-1b .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15579375.001).
  • [ISSN] 1043-4666
  • [Journal-full-title] Cytokine
  • [ISO-abbreviation] Cytokine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Integrin alpha1; 0 / Interleukin-12 Subunit p40; 0 / Protein Subunits; 0 / Recombinant Proteins; 0 / Tumor Necrosis Factor-alpha; 0 / Vascular Cell Adhesion Molecule-1; 126547-89-5 / Intercellular Adhesion Molecule-1; 145155-23-3 / Interferon beta-1b; 187348-17-0 / Interleukin-12; 77238-31-4 / Interferon-beta
  •  go-up   go-down


6. Berhouma M, Bahri K, Houissa S, Zemmel I, Khouja N, Aouidj L, Jemel H, Khaldi M: [Management of intramedullary spinal cord tumors: surgical considerations and results in 45 cases]. Neurochirurgie; 2009 Jun;55(3):293-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of intramedullary spinal cord tumors: surgical considerations and results in 45 cases].
  • BACKGROUND AND PURPOSE: Intramedullary spinal cord tumors (IMSCT) are relatively rare neoplasms, accounting for less than 5% of all central nervous system tumors.
  • The optimum management of these tumors still remains controversial.
  • The cervical location of the tumor was the most common (20 cases).
  • The large majority of patients had histologically-proven low-grade tumors composed essentially of astrocytomas (44,4%) and ependymomas (28,8%).
  • Determinant predictors for a good outcome after surgery of IMSCT are histological type of lesion, total removal of the tumor and a satisfactory neurological status before surgery.
  • [MeSH-major] Spinal Cord Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Biopsy. Child. Child, Preschool. Disease Progression. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Microsurgery. Middle Aged. Spinal Cord / pathology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18538355.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


7. Takano T, Akahira J, Moriya T, Murakami T, Tanaka M, Goto M, Niikura H, Ito K, Mikami Y, Okamura K, Yaegashi N: Primary ependymoma of the ovary: a case report and literature review. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1138-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ependymoma is a glioma with differentiation toward ependymal cells that usually arises in the central nervous system.
  • Microscopic examination revealed a highly cellular tumor composed of small cells with hyperchromatic, round-to-oval nuclei and scanty cytoplasm.
  • Although rare, primary ovarian ependymoma must be kept in mind in the differential diagnosis of ovarian tumors, especially in young women.
  • [MeSH-major] Ependymoma / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Female. Gynecologic Surgical Procedures. Humans. Reoperation

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343197.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 16
  •  go-up   go-down


8. Rognoni P, Chiarelli LR, Comincini S, Azzalin A, Miracco C, Valentini G: Biochemical signatures of doppel protein in human astrocytomas to support prediction in tumor malignancy. J Biomed Biotechnol; 2010;2010:301067
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biochemical signatures of doppel protein in human astrocytomas to support prediction in tumor malignancy.
  • Doppel (Dpl) is a membrane-bound glycoprotein mainly expressed in the testis of adult healthy people.
  • It is generally absent in the central nervous system, but its coding gene sequence is ectopically expressed in astrocytoma specimens and in derived cell lines.
  • Importantly, Dpl exhibited different cellular localizations and altered glycan moieties composition, depending on the tumor grade.
  • To find associations between glial tumor progression and Dpl biochemical features, predictive bioinformatics approaches were produced.
  • Taken together, these findings show that in astrocytomas, Dpl undergoes different molecular processes that might constitute additional helpful tools to characterize the glial tumor progression.
  • [MeSH-major] Astrocytoma / pathology. Biomarkers, Tumor. Brain Neoplasms / pathology. Prions / chemistry. Prions / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Membrane / metabolism. Child. Cluster Analysis. Cytoplasm / metabolism. Disease Progression. Female. GPI-Linked Proteins / chemistry. GPI-Linked Proteins / isolation & purification. GPI-Linked Proteins / metabolism. Humans. Immunohistochemistry. Male. Middle Aged. N-Acetylneuraminic Acid / metabolism. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 1999 Dec 6;1473(1):21-34 [10580127.001]
  • [Cites] Cell Oncol. 2008;30(4):337-47 [18607068.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):654-8 [11212264.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2352-7 [11226243.001]
  • [Cites] Biochim Biophys Acta. 2001 Aug 31;1551(1):M19-27 [11553418.001]
  • [Cites] EMBO J. 2002 Jul 15;21(14):3652-8 [12110578.001]
  • [Cites] J Biol Chem. 2002 Nov 8;277(45):43071-8 [12200435.001]
  • [Cites] Br Med Bull. 2003;66:35-42 [14522847.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3a):1507-17 [15274317.001]
  • [Cites] Anal Biochem. 1981 Nov 15;118(1):131-7 [6175244.001]
  • [Cites] Electrophoresis. 1999 Feb;20(2):362-71 [10197444.001]
  • [Cites] J Mol Biol. 1999 Oct 1;292(4):797-817 [10525406.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Proteomics. 2004 Dec;4(12):3665-85 [15543535.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3624-32 [15897557.001]
  • [Cites] Oncol Rep. 2006 Dec;16(6):1325-32 [17089057.001]
  • [Cites] Oncol Rep. 2007 May;17(5):989-96 [17390034.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] J Biol Chem. 2000 Sep 1;275(35):26834-41 [10842180.001]
  • (PMID = 20981146.001).
  • [ISSN] 1110-7251
  • [Journal-full-title] Journal of biomedicine & biotechnology
  • [ISO-abbreviation] J. Biomed. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / PRND protein, human; 0 / Prions; GZP2782OP0 / N-Acetylneuraminic Acid
  • [Other-IDs] NLM/ PMC2957138
  •  go-up   go-down


9. Doyle DM, Einhorn LH: Delayed effects of whole brain radiotherapy in germ cell tumor patients with central nervous system metastases. Int J Radiat Oncol Biol Phys; 2008 Apr 1;70(5):1361-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delayed effects of whole brain radiotherapy in germ cell tumor patients with central nervous system metastases.
  • PURPOSE: Central nervous system (CNS) metastases are uncommon in patients with germ cell tumors, with an incidence of 2-3%.
  • CNS metastases have been managed with whole brain radiotherapy (WBRT) and concomitant cisplatin-based combination chemotherapy.
  • Our previous study did not observe serious CNS toxicity (Int J Radiat Oncol Biol Phys 1991;22:17-22).
  • We now report on 5 patients who developed delayed significant CNS toxicity.
  • PATIENTS AND METHODS: We observed 5 patients with delayed CNS toxicity.
  • Of the 5 patients, 3 had CNS metastases at diagnosis and 2 developed relapses with CNS metastases.
  • The median time from WBRT to CNS symptoms was 72 months (range, 9-228).
  • CONCLUSION: Whole brain radiotherapy is not innocuous in young patients with germ cell tumors and can cause late CNS toxicity.
  • [MeSH-major] Brain / radiation effects. Brain Neoplasms / radiotherapy. Cranial Irradiation / adverse effects. Neoplasms, Germ Cell and Embryonal / radiotherapy. Radiation Injuries / complications. Testicular Neoplasms
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Choriocarcinoma / blood. Choriocarcinoma / drug therapy. Choriocarcinoma / radiotherapy. Choriocarcinoma / secondary. Chorionic Gonadotropin / blood. Cisplatin / administration & dosage. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Fatal Outcome. Humans. Leukoencephalopathy, Progressive Multifocal / etiology. Lung Neoplasms / secondary. Male. Neoplasm Proteins / blood. Radiotherapy Dosage. Salvage Therapy / methods. Stem Cell Transplantation. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1300-2 [18374219.001]
  • (PMID = 18374223.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 0 / Neoplasm Proteins; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Wu ZB, Yu CJ, Guan SS: Posterior petrous meningiomas: 82 cases. J Neurosurg; 2005 Feb;102(2):284-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All Type I tumors were completely resected, and the rate of anatomical preservation of facial nerve was 100% and functional preservation was 93%.
  • The rate of anatomical preservation of facial nerve in patients with this tumor type was 95%, whereas functional preservation was 73%.
  • It is more difficult for Types II and III tumors to be resected radically than Type I lesions, and postoperative functional outcomes are significantly worse accordingly.
  • The primary principles in dealing with this disease entity include preservation of vital vascular and central nervous system structures and total resection of the tumor as much as possible.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Petrous Bone / surgery
  • [MeSH-minor] Adult. Aged. Cavernous Sinus / pathology. Cranial Nerve Neoplasms / classification. Cranial Nerve Neoplasms / diagnosis. Cranial Nerve Neoplasms / surgery. Craniotomy. Ear Neoplasms / classification. Ear Neoplasms / diagnosis. Ear Neoplasms / surgery. Facial Nerve Injuries / diagnosis. Female. Follow-Up Studies. Hearing Loss, Sensorineural / diagnosis. Humans. Labyrinth Diseases / classification. Labyrinth Diseases / diagnosis. Labyrinth Diseases / surgery. Magnetic Resonance Imaging. Male. Microsurgery. Middle Aged. Neoplasm Invasiveness. Postoperative Complications / diagnosis. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15739556.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Mao XC, Su ZP, Yu WQ, Zheng WM, Zeng YJ: Familial and genetic researches on three Chinese families with von Hippel-Lindau disease. Neurol Res; 2009 Sep;31(7):743-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Hemangioblastoma of the central nervous system (CNS) occur as sporadic tumors or as a part of von Hippel-Lindau (VHL) disease, an autosomal dominant hereditary tumor syndrome caused by germline mutation of the VHL tumor suppressor gene.
  • Twenty VHL disease patients in the three families have the most common manifestation of CNS hemangioblastoma.
  • The CNS hemangioblastoma is the early manifestation in VHL disease.
  • It is recommended that every patient with CNS hemangioblastoma should be screened for VHL gene mutation.
  • [MeSH-major] Genetic Predisposition to Disease. Mutation / genetics. Von Hippel-Lindau Tumor Suppressor Protein / genetics. von Hippel-Lindau Disease / genetics
  • [MeSH-minor] Adolescent. Adult. Asian Continental Ancestry Group / ethnology. Brain Neoplasms / etiology. Brain Neoplasms / genetics. DNA Mutational Analysis. Female. Genetic Testing. Genotype. Hemangioblastoma / etiology. Hemangioblastoma / genetics. Humans. Male. Middle Aged. Phenotype. Retrospective Studies. Severity of Illness Index. Young Adult

  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19133167.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  •  go-up   go-down


12. Suri A, Ahmad FU, Mahapatra AK: Extradural transcavernous approach to cavernous sinus hemangiomas. Neurosurgery; 2007 Mar;60(3):483-8; discussion 488-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor was accessed through its maximum bulge through either the lateral or anterolateral triangle.
  • The tumor was removed via rapid decompression, coagulation of the feeder from the meningohypophyseal trunk, and dissection along the cranial nerves.
  • All but one patient had complete tumor excision.
  • [MeSH-major] Cavernous Sinus / surgery. Hemangioma, Cavernous, Central Nervous System / surgery. Neurosurgical Procedures / methods
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17327792.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Robertus JL, Harms G, Blokzijl T, Booman M, de Jong D, van Imhoff G, Rosati S, Schuuring E, Kluin P, van den Berg A: Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. Mod Pathol; 2009 Apr;22(4):547-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma.
  • Apart from 19 nodal cases without extranodal dissemination (stages I and II), we selected two groups with unambiguous stages I and II extranodal presentation; 9 cases of primary central nervous system, 11 cases of primary testicular and 11 cases of other primary extranodal diffuse large B-cell lymphomas.
  • In situ hybridization for the most differentially expressed miRNAs was performed to show miRNA expression in tumor cells, but not in background cells.
  • MiR-17-5p showed a significant higher expression level in the central nervous system compared with testicular and nodal diffuse large B-cell lymphomas (P<0.05).
  • MiR-127 levels were significantly higher in testicular than in central nervous system and in nodal diffuse large B-cell lymphomas (P<0.05).
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. MicroRNAs / biosynthesis. Testicular Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Germinal Center / pathology. Humans. In Situ Hybridization. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19287466.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MIRN17 microRNA, human; 0 / MicroRNAs
  •  go-up   go-down


14. Samdani AF, Torre-Healy A, Khalessi A, McGirt M, Jallo GI, Carson B: Intraventricular ganglioglioma: a short illustrated review. Acta Neurochir (Wien); 2009 Jun;151(6):635-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The following review of the literature describes the ganglioglioma, an uncommon mixed glioneuronal neoplasm, most often of low-grade histology, with a small, albeit well-documented, malignant potential.
  • These tumors exhibit a strong epileptogenic propensity and most often present as new onset seizures or are discovered after a long history of refractory epilepsy.
  • Morphologically, the neoplasm is often cystic with an enhancing mural nodule, but can also be entirely solid.
  • A superior parietal lobule approach offered excellent surgical access for tumor removal and the patient has remained free of neurological deficits following surgery.
  • Regardless of location within the central nervous system, ganglioglioma should be on the differential diagnosis for any cystic mass with a mural nodule, particularly in the setting of epilepsy.
  • [MeSH-major] Brain / pathology. Cerebral Ventricle Neoplasms / pathology. Ganglioglioma / pathology. Lateral Ventricles / pathology. Neurosurgical Procedures / methods
  • [MeSH-minor] Adult. Aged. Central Nervous System Cysts / pathology. Central Nervous System Cysts / radiography. Central Nervous System Cysts / surgery. Child. Diagnosis, Differential. Dizziness / etiology. Epilepsy / etiology. Female. Humans. Magnetic Resonance Imaging. Male. Treatment Outcome. Vision, Low / etiology. Young Adult

  • Genetic Alliance. consumer health - Ganglioglioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19290468.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 49
  •  go-up   go-down


15. Sezgin C, Gokmen E, Esassolak M, Ozdemir N, Goker E: Risk factors for central nervous system metastasis in patients with metastatic breast cancer. Med Oncol; 2007;24(2):155-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for central nervous system metastasis in patients with metastatic breast cancer.
  • AIMS: Patients with metastatic breast cancer (MBC) and central nervous system (CNS) involvement have an impaired survival and quality of life.
  • In this study, we investigated the risk factors for CNS metastasis among patients with MBC.
  • METHODS: The risk factors for development of CNS metastasis were analyzed in 154 patients with MBC.
  • RESULTS: Median OS was significantly poorer for patients with CNS metastasis as compared with patients with no CNS metastasis (OS, 23 mo vs 30 mo, respectively;p = 0.03).
  • Ki-67 and p53 overexpressions by IHC, and lung metastasis as the first site of relapse, were associated with a higher risk of developing CNS metastasis in the univariate analysis (p <or= 0.05).
  • The presence of lung metastasis (odds ratio [OR]= 2.82, 95% confidence interval [CI]: 1.13-7.00,p = 0.02) and p53 overexpression (OR = 2.44, 95% CI: 0.99-6.00,p = 0.05) were the two predictive factors associated with occurrence of CNS metastasis in the multivariate analysis.
  • CONCLUSIONS: In this study, the presences of lung metastasis as the first site of relapse and p53 overexpression were predictive for the occurrence of CNS metastasis in patients with MBC.
  • Life expectancy of patients with CNS metastasis is significantly shorter than those without CNS metastasis.
  • [MeSH-major] Breast Neoplasms / pathology. Central Nervous System Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lung Neoplasms / secondary. Middle Aged. Predictive Value of Tests. Prevalence. Prognosis. Registries. Risk Factors. Survival Analysis. Tumor Suppressor Protein p53 / analysis


16. Kim K, Wu HG, Kim HJ, Sung MW, Kim KH, Lee SH, Heo DS, Kim HJ, Park CI: Intensity-modulated radiation therapy with simultaneous integrated boost technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Head Neck; 2009 Sep;31(9):1121-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dose prescription of IMRT was as follows: 67.5 Gy at 2.25 Gy/fraction to postchemotherapy gross tumor, 54 to 60 Gy at 1.8 to 2 Gy/fraction to subclinical disease, and 48 Gy at 1.6 Gy/fraction to elective neck.
  • Definition of gross tumor volume by postchemotherapy extent of disease was also feasible.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Nasopharyngeal Neoplasms / radiotherapy. Neoadjuvant Therapy. Radiotherapy, Intensity-Modulated
  • [MeSH-minor] Adult. Aged. Central Nervous System / radiation effects. Disease-Free Survival. Female. Humans. Male. Middle Aged. Radiation Dosage. Radiotherapy Dosage. Young Adult

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19340863.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


17. Bradly DP, Reddy VB, Cochran E, Gattuso P: Comparison of cytological features of myxopapillary ependymomas on crush preparations. Diagn Cytopathol; 2009 Aug;37(8):607-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myxopapillary ependymoma (ME) is a rare neoplasm found predominantly in the sacro-coccygeal region in adults and is characterized by its distinct epithelial and stromal components.
  • The epithelial component of ME is strikingly similar for all six cases showing tumor cells appearing singly or in loose clusters, most with papillary branching.
  • These aforementioned characteristics can be utilized to distinguish ME from other primary and metastatic tumors such as meningioma, adenoid cystic carcinoma, chordoma, mucinous adenocarcinoma, chondrosarcoma, and germ cell tumors.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Cytological Techniques / methods. Ependymoma / pathology
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19459157.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Jansen AM, Nässel DR, Madsen KL, Jung AG, Gether U, Kjaerulff O: PICK1 expression in the Drosophila central nervous system primarily occurs in the neuroendocrine system. J Comp Neurol; 2009 Nov 20;517(3):313-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PICK1 expression in the Drosophila central nervous system primarily occurs in the neuroendocrine system.
  • To study PICK1 in an intact system, we characterized PICK1 expression immunohistochemically in the adult and larval Drosophila central nervous system.
  • In contrast, we detected robust PICK1 immunolabeling of peptidergic neurons in the neuroendocrine system, which express the transcription factor DIMM and the amidating enzyme peptidylglycine-alpha-hydroxylating monooxygenase (PHM).
  • We conclude that PICK1 may serve an important role in the neuroendocrine system both in insects and vertebrates.
  • [MeSH-minor] Animals. Animals, Genetically Modified. Brain / growth & development. Brain / metabolism. Cell Line, Tumor. Dopamine / metabolism. Glutamic Acid / metabolism. Immunohistochemistry. Larva / growth & development. Larva / metabolism. Mutation. Neurosecretory Systems / growth & development. Neurosecretory Systems / metabolism. Peripheral Nervous System / growth & development. Peripheral Nervous System / metabolism. Rats. Spinal Cord / growth & development. Spinal Cord / metabolism. gamma-Aminobutyric Acid / metabolism


19. Pfister C, Ritz R, Endemann E, Schittenhelm J, Bornemann A, Tatagiba MS, Roser F: Evidence of ubiquitous in vivo and in vitro expression of pro-apoptotic Smac/DIABLO protein in meningioma cell lines. Oncol Rep; 2009 May;21(5):1181-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although meningiomas are one of the most common tumors in the central nervous system, the adjuvant treatment for recurrent or malignant meningiomas is not satisfactory.
  • Changes in apoptosis mechanisms play important roles in tumor pathogenesis.
  • [MeSH-major] Meningeal Neoplasms / metabolism. Meningioma / metabolism. Mitochondrial Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Intracellular Signaling Peptides and Proteins / genetics. Male. Middle Aged. RNA, Neoplasm / biosynthesis. RNA, Neoplasm / genetics. Tumor Cells, Cultured. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19360292.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DIABLO protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Mitochondrial Proteins; 0 / RNA, Neoplasm
  •  go-up   go-down


20. Marinovic T, Grahovac G, Habek M, Lambasa S, Tomac D: Simultaneous conus medullaris ependymoma and cerebellar astrocytoma in the same patient. Clin Neuropathol; 2009 May-Jun;28(3):173-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple primary tumors in the central nervous system of different histological cell types are uncommon.
  • The suggested mechanism of this association is that primitive multipotent cells might have been displaced in the different CNS areas and developed in different tumor cells.
  • Multiplicity of primary CNS tumors should be considered in certain occasions, when clinical symptoms and signs are pointing in that direction.
  • [MeSH-major] Astrocytoma / pathology. Cerebellar Neoplasms / pathology. Ependymoma / pathology. Neoplasms, Multiple Primary / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adult. Cauda Equina / pathology. Cauda Equina / surgery. Female. Humans. Magnetic Resonance Imaging. Neurosurgical Procedures

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19537133.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


21. Agha MM, Williams JI, Marrett L, To T, Zipursky A, Dodds L: Congenital abnormalities and childhood cancer. Cancer; 2005 May 1;103(9):1939-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The examination of specific characteristics of neoplasms diagnosed in children have suggested that a significant proportion can be attributed to a genetic mutation or genetic predisposition.
  • Through this study, the risk of developing cancer by age at diagnosis, effects of birth characteristics on cancer risk, and possible associations between specific anomalies and tumor types were examined.
  • Children with birth defects were found to be at a higher risk for developing leukemia (RR of 2.7; 95% CI, 2.1-3.6), tumors of the central nervous system (RR of 2.5; 95% CI, 1.8-3.4), sympathetic nervous system tumors (RR of 2.2; 95% CI, 1.4-3.4), and soft tissue sarcomas (RR of 1.9; 95% CI, 1.0-3.5).
  • Among children with birth defects, children with Down syndrome, nervous system anomalies, and anomalies of the urinary system had the highest incidence rates of cancer.
  • [MeSH-major] Central Nervous System Neoplasms / etiology. Congenital Abnormalities / pathology. Down Syndrome / etiology. Leukemia / etiology. Sarcoma / etiology
  • [MeSH-minor] Adult. Case-Control Studies. Child. Cohort Studies. Female. Humans. Incidence. Infant, Newborn. Male. Maternal Age. Medical Record Linkage. Risk Factors


22. Lunsford LD, Khan AA, Niranjan A, Kano H, Flickinger JC, Kondziolka D: Stereotactic radiosurgery for symptomatic solitary cerebral cavernous malformations considered high risk for resection. J Neurosurg; 2010 Jul;113(1):23-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median malformation volume was 1.31 ml, and the median tumor margin dose was 16 Gy.
  • [MeSH-major] Hemangioma, Cavernous, Central Nervous System / surgery. Radiosurgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Cross-Sectional Studies. Female. Follow-Up Studies. Humans. Infant. Intracranial Hemorrhages / diagnosis. Intracranial Hemorrhages / epidemiology. Intracranial Hemorrhages / surgery. Magnetic Resonance Imaging. Male. Middle Aged. Neurologic Examination. Neuronavigation. Postoperative Complications / diagnosis. Postoperative Complications / epidemiology. Postoperative Hemorrhage / diagnosis. Postoperative Hemorrhage / epidemiology. Postoperative Hemorrhage / surgery. Reoperation / statistics & numerical data. Retrospective Studies. Risk. Secondary Prevention. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2010 Jul;113(1):16-21; discussion 21-2 [20170301.001]
  • (PMID = 20170299.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


23. Obara H, Nishimura S, Hayashi N, Numagami Y, Inoue T, Kubo K, Kaimori M, Nishijima M: [Intracranial granulocytic sarcoma in a patient with acute myeloid leukemia]. No To Shinkei; 2006 Sep;58(9):797-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Granulocytic sarcoma (GS) is extramedullary tumor composed of immature leukemic cells.
  • GS is presenting usually as a complication during the course of hematologic neoplasm, such as acute myeloblastic leukemia as well as myeloproliferative and myelodysplastic syndrome.
  • The tumor was also called chroloma based on the green color of the tumorous mass.
  • Central nervous system manifestations of GS are extremely rare.
  • Operative findings revealed the color of the hard tumor was greenish, which suggested the tumor was chroloma.
  • Histological findings showed the tumor was GS.
  • This is the first case report of AML: M7 with GS in the central nervous system.
  • [MeSH-major] Brain Neoplasms / complications. Leukemia, Myeloid, Acute / complications. Neoplasms, Multiple Primary / pathology. Occipital Lobe. Sarcoma, Myeloid / complications
  • [MeSH-minor] Adult. Humans. Male


24. Le BH, Towfighi J, Kapadia SB, Lopes MB: Comparative immunohistochemical assessment of craniopharyngioma and related lesions. Endocr Pathol; 2007;18(1):23-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Craniopharyngioma / pathology. Keratin-20 / metabolism. Keratin-8 / metabolism. Pituitary Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Central Nervous System Cysts / metabolism. Central Nervous System Cysts / pathology. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Reproducibility of Results. Xanthogranuloma, Juvenile / metabolism. Xanthogranuloma, Juvenile / pathology

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Front Horm Res. 2006;34:105-26 [16474218.001]
  • [Cites] Pathol Res Pract. 2001;197(11):735-42 [11770017.001]
  • [Cites] Diagn Cytopathol. 1999 Mar;20(3):137-47 [10086237.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Nov;84(11):3972-82 [10566636.001]
  • [Cites] J Neurosurg. 2004 Oct;101(4):577-84 [15481709.001]
  • [Cites] J Neurosurg. 1991 Apr;74(4):535-44 [2002366.001]
  • [Cites] Acta Neuropathol. 1999 Apr;97(4):377-82 [10208277.001]
  • [Cites] Acta Neurochir (Wien). 2001;143(2):147-51 [11459086.001]
  • [Cites] Acta Neurochir (Wien). 1990;107(3-4):93-101 [1706558.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1983 Nov;56(5):502-11 [6196702.001]
  • [Cites] Brain Tumor Pathol. 1997;14(1):41-5 [9384801.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):237-50 [9950494.001]
  • [Cites] Arch Pathol Lab Med. 2002 Oct;126(10):1174-8 [12296753.001]
  • [Cites] J Neurosurg. 2005 Feb;102(2):189-93 [15739543.001]
  • [Cites] J Neurosurg. 1998 Oct;89(4):547-51 [9761047.001]
  • [Cites] J Oral Pathol Med. 1997 Sep;26(8):349-55 [9379423.001]
  • [Cites] Neurosurgery. 2000 Feb;46(2):291-302; discussion 302-5 [10690718.001]
  • [Cites] Surg Neurol. 1992 Aug;38(2):106-9 [1509341.001]
  • [Cites] Acta Neurochir (Wien). 1993;124(2-4):139-43 [7508161.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):206-14 [7616262.001]
  • [Cites] Noshuyo Byori. 1993;10(1):43-52 [7693227.001]
  • (PMID = 17652797.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-20; 0 / Keratin-8
  •  go-up   go-down


25. Okano H: Strategies toward CNS-regeneration using induced pluripotent stem cells. Genome Inform; 2009 Oct;23(1):217-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategies toward CNS-regeneration using induced pluripotent stem cells.
  • Surprisingly, SNSs derived from c-Myc minus iPS cells generated without drug selection showed robust tumorigenesis, in spite of their potential to contribute adult chimeric mice without tumor formation.
  • [MeSH-major] Central Nervous System / physiology. Pluripotent Stem Cells / cytology. Regeneration

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20180278.001).
  • [ISSN] 0919-9454
  • [Journal-full-title] Genome informatics. International Conference on Genome Informatics
  • [ISO-abbreviation] Genome Inform
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


26. Deen HG, Miller DA, Kostick DA, Jaeckle KA: Removal of an orbital metallic foreign body to facilitate magnetic resonance imaging: technical case report. Neurosurgery; 2006 May;58(5):E999; discussion E999
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE AND IMPORTANCE: Magnetic resonance imaging (MRI) is the imaging modality of choice for brain tumors and other lesions of the central nervous system.
  • CLINICAL PRESENTATION: Two patients, one with a posterior fossa mass and one with suspected central nervous system lymphoma, were seen at our institution.
  • The first patient underwent posterior fossa craniotomy and removal of the tumor, which proved to be a medulloblastoma.
  • CONCLUSION: Two patients with central nervous system tumors underwent removal of a metal fragment in the orbit for the specific purpose of facilitating MRI scans.
  • [MeSH-minor] Adult. Cerebellar Neoplasms / diagnosis. Humans. Male. Medulloblastoma / diagnosis. Meningeal Neoplasms / diagnosis. Middle Aged. Orbit / radiography. Orbit / surgery

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16639311.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ferric Compounds; 1317-54-0 / ferrite
  •  go-up   go-down


27. Takehara A, Hosokawa M, Eguchi H, Ohigashi H, Ishikawa O, Nakamura Y, Nakagawa H: Gamma-aminobutyric acid (GABA) stimulates pancreatic cancer growth through overexpressing GABAA receptor pi subunit. Cancer Res; 2007 Oct 15;67(20):9704-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gamma-aminobutyric acid (GABA) functions primarily as an inhibitory neurotransmitter in the mature central nervous system, and GABA/GABA receptors are also present in nonneural tissues, including cancer, but their precise function in nonneuronal or cancerous cells has thus far been poorly defined.
  • We also found the expression of this peripheral type GABAA receptor subunit in few adult human organs.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / metabolism. Carcinoma, Pancreatic Ductal / pathology. GABA Agents / pharmacology. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Receptors, GABA-A / biosynthesis. gamma-Aminobutyric Acid / pharmacology
  • [MeSH-minor] Calcium / metabolism. Cell Growth Processes / drug effects. Cell Growth Processes / physiology. Cell Line, Tumor. Humans. MAP Kinase Signaling System / drug effects. RNA, Small Interfering / genetics


28. Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF: MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol; 2005 Nov-Dec;26(10):2466-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: For patients with malignant gliomas, clinical data-including age, perioperative Karnofsky Performance Status (KPS), and tumor resection-and tumor imaging features-including necrosis and edema-have been found to correlate with survival.
  • RESULTS: As expected, age and KPS scores had significant prognostic value for both tumor grades.
  • For GBM, univariable analysis revealed the following imaging features to be significant, (hazard ratios in parentheses): noncontrast-enhancing tumor (nCET, 0.55), edema (1.62), satellites (1.74), and multifocality (4.34).
  • For grade III tumors, the Cox hazard ratio for necrosis was 4.43 (P = .014) and correlated with a poor outcome and survival rates comparable to GBM patients.
  • CONCLUSION: Of 15 tumor imaging features in GBM patients, only nCET, edema, and multifocality/satellites are statistically significant prognostic indicators.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Glioma / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Age Factors. Brain Edema / classification. Brain Edema / diagnosis. Female. Follow-Up Studies. Glioblastoma / classification. Glioblastoma / diagnosis. Glioblastoma / mortality. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm, Residual. Prognosis. Proportional Hazards Models. Reproducibility of Results. Survival Analysis. Survival Rate

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16286386.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Policarpio-Nicolas ML, Le BH, Mandell JW, Lopes MB: Granular cell tumor of the neurohypophysis: report of a case with intraoperative cytologic diagnosis. Diagn Cytopathol; 2008 Jan;36(1):58-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell tumor of the neurohypophysis: report of a case with intraoperative cytologic diagnosis.
  • Cytological techniques including touch and smear preparations are very useful diagnostic modality in the evaluation of central nervous system (CNS) lesions and, in many instances, may be effectively used as the sole modality of tissue preparation for intraoperative consultation.
  • Cytologic preparations offer many advantages over frozen sections for CNS specimens.
  • We describe the cytologic diagnosis of a granular cell tumor (GCT) of the neurohypophysis in a 33-year-old male who presented with headache and blurred vision.
  • [MeSH-major] Granular Cell Tumor / diagnosis. Pituitary Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biopsy. Cytological Techniques. Humans. Intraoperative Period. Male

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18064694.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD: IDH1 and IDH2 mutations in gliomas. N Engl J Med; 2009 Feb 19;360(8):765-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A recent genomewide mutational analysis of glioblastomas (World Health Organization [WHO] grade IV glioma) revealed somatic mutations of the isocitrate dehydrogenase 1 gene (IDH1) in a fraction of such tumors, most frequently in tumors that were known to have evolved from lower-grade gliomas (secondary glioblastomas).
  • METHODS: We determined the sequence of the IDH1 gene and the related IDH2 gene in 445 central nervous system (CNS) tumors and 494 non-CNS tumors.
  • Tumors without mutations in IDH1 often had mutations affecting the analogous amino acid (R172) of the IDH2 gene.
  • Tumors with IDH1 or IDH2 mutations had distinctive genetic and clinical characteristics, and patients with such tumors had a better outcome than those with wild-type IDH genes.

  • Genetics Home Reference. consumer health - IDH1 gene.
  • Genetics Home Reference. consumer health - IDH2 gene.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827855335 for PMID:19228619 [PharmGKB] .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Massachusetts Medical Society
  • [Cites] Cancer Res. 1996 Jan 1;56(1):150-3 [8548755.001]
  • [Cites] Oncogene. 1996 Sep 5;13(5):983-94 [8806688.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1175-90 [7977648.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2965-9 [1557402.001]
  • [Cites] Science. 1997 Mar 28;275(5308):1943-7 [9072974.001]
  • [Cites] Biochemistry. 1997 Nov 4;36(44):13743-7 [9354646.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):375-86 [10433931.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Genes Dev. 2007 Nov 1;21(21):2683-710 [17974913.001]
  • [Cites] Free Radic Res. 2008 Jul;42(7):618-24 [18608518.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):492-507 [18669428.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8673-7 [18974108.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3089-94 [14970324.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33946-57 [15173171.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Oct;84(19):6899-903 [3477813.001]
  • [Cites] Nature. 1989 Dec 7;342(6250):705-8 [2531845.001]
  • [CommentIn] N Engl J Med. 2009 May 21;360(21):2248; author reply 2249 [19458374.001]
  • [CommentIn] N Engl J Med. 2009 May 21;360(21):2248-9; author reply 2249 [19469031.001]
  • [CommentIn] N Engl J Med. 2009 Feb 19;360(8):813-5 [19228626.001]
  • (PMID = 19228619.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA043460-27; United States / NCI NIH HHS / CA / CA57345; United States / NCI NIH HHS / CA / R01CA118822; United States / NCI NIH HHS / CA / R37 CA043460; United States / NCI NIH HHS / CA / R37 CA043460-27; United States / NCI NIH HHS / CA / P50 CA108786; United States / NINDS NIH HHS / NS / P50 NS020023; United States / NCI NIH HHS / CA / 2P30-CA-14236; United States / NCI NIH HHS / CA / 5P50-CA-108786; United States / NCI NIH HHS / CA / CA121113; United States / NCI NIH HHS / CA / CA062924-150012; United States / NCI NIH HHS / CA / R37 CA043460-26; United States / NCI NIH HHS / CA / 5R37-CA-11898; United States / NCI NIH HHS / CA / R37CA11898-34; United States / NCI NIH HHS / CA / R01 CA121113; United States / NCI NIH HHS / CA / R01 CA140316; United States / NCI NIH HHS / CA / CA43460; United States / NCI NIH HHS / CA / CA043460-26; United States / NCI NIH HHS / CA / R01 CA121113-04; United States / NINDS NIH HHS / NS / NS20023-21; United States / NCI NIH HHS / CA / CA057345-17; United States / NCI NIH HHS / CA / R37 CA057345-17; United States / NCI NIH HHS / CA / R37 CA057345; United States / NCI NIH HHS / CA / P30 CA014236; United States / NCI NIH HHS / CA / P50 CA062924-150012; United States / NCI NIH HHS / CA / R01 CA057345; United States / NCI NIH HHS / CA / R01 CA118822; United States / NINDS NIH HHS / NS / 5P50-NS-20023; United States / NCI NIH HHS / CA / R37 CA011898
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.41 / isocitrate dehydrogenase 2, human
  • [Other-IDs] NLM/ NIHMS107443; NLM/ PMC2820383
  •  go-up   go-down


31. Vaglio A, Manenti L, Mancini C, Chierici E, Cobelli R, Bacci F, Palmisano A, Buzio C, Bignardi L, Maggiore U: EBV-associated leukoencephalopathy with late onset of central nervous system lymphoma in a kidney transplant recipient. Am J Transplant; 2010 Apr;10(4):947-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV-associated leukoencephalopathy with late onset of central nervous system lymphoma in a kidney transplant recipient.
  • Central nervous system (CNS) lymphoma is a rare posttransplant lymphoproliferative disorder (PTLD), which usually has a poor outcome.
  • We here describe the case of a renal transplant patient who was initially diagnosed as having Epstein-Barr virus (EBV)-associated leukoencephalopathy and ultimately developed EBV-positive CNS lymphoma.
  • This case illustrates the potential pathophysiological relationships between EBV infection, leukoencephalopathy and CNS lymphoma; although a long time elapsed from the initial neurological illness to CNS lymphoma, a link between these two conditions cannot be excluded.
  • [MeSH-major] Brain Neoplasms / diagnosis. Herpesvirus 4, Human / pathogenicity. Kidney Transplantation. Leukoencephalopathies / diagnosis. Lymphoma / diagnosis. Tumor Virus Infections / diagnosis
  • [MeSH-minor] Adult. Antiviral Agents / therapeutic use. Female. Humans. Kidney Failure, Chronic / surgery. Magnetic Resonance Imaging. Positron-Emission Tomography

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20420644.001).
  • [ISSN] 1600-6143
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents
  •  go-up   go-down


32. Simonová G, Novotny J Jr, Liscák R: Low-grade gliomas treated by fractionated gamma knife surgery. J Neurosurg; 2005 Jan;102 Suppl:19-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: The authors sought to evaluate local tumor control, complications, and progression-free survival in patients harboring low-grade gliomas who were treated with Leksell gamma knife surgery (GKS).
  • Partial or complete tumor regression was achieved in 83% of patients with a median time to response of 18 months.
  • CONCLUSIONS: Relatively high local tumor control with minimal complications was achieved.
  • [MeSH-major] Central Nervous System Neoplasms / surgery. Glioma / surgery. Radiosurgery / instrumentation. Survivors / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Equipment Design. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15662774.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Kleinsasser NH, Sassen AW, Semmler MP, Staudenmaier R, Harréus UA, Richter E: [Does nicotine add to the carcinogenic strain of tobacco smoke?]. HNO; 2006 May;54(5):369-72, 374-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: It is accepted that nicotine in tobacco smoke causes addiction via nicotinic acetylcholine receptors in the central nervous system.
  • However, more recently data have accumulated which suggest that nicotine may add to the cancer risk by stimulating cellular growth via non-neuronal acetylcholine receptors, by suppressing apoptosis, and by inducing angiogenesis not only in atheromatous plaques but also in tumors.
  • Thus, nicotine may contribute directly to tumor initiation resulting from smoking.
  • [MeSH-major] Cell Transformation, Neoplastic / chemically induced. Mutagenicity Tests. Nicotine / toxicity. Otorhinolaryngologic Neoplasms / chemically induced. Smoking / adverse effects. Smoking Cessation. Tobacco Use Disorder / pathology
  • [MeSH-minor] Administration, Cutaneous. Adult. Chewing Gum. Comet Assay. DNA Adducts. DNA Mutational Analysis. Dose-Response Relationship, Drug. Humans. In Vitro Techniques. Male. Middle Aged. Nasal Mucosa / drug effects. Nasal Mucosa / pathology. Respiratory Mucosa / drug effects. Respiratory Mucosa / pathology

  • MedlinePlus Health Information. consumer health - Quitting Smoking.
  • MedlinePlus Health Information. consumer health - Smoking.
  • Hazardous Substances Data Bank. NICOTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Toxicol Sci. 2004 Sep;81(1):121-32 [15178808.001]
  • [Cites] J Agric Food Chem. 2002 Aug 14;50(17):4909-15 [12166981.001]
  • [Cites] HNO. 2001 May;49(5):378-81 [11405146.001]
  • [Cites] Mutat Res. 1995 Oct;344(3-4):95-102 [7491133.001]
  • [Cites] Anat Rec A Discov Mol Cell Evol Biol. 2003 Jan;270(1):51-8 [12494489.001]
  • [Cites] Toxicology. 2002 Sep 30;179(1-2):95-103 [12204546.001]
  • [Cites] Carcinogenesis. 1994 May;15(5):1061-4 [8200069.001]
  • [Cites] Mutat Res. 1982 Mar;101(1):39-43 [7043247.001]
  • [Cites] J Toxicol Environ Health. 1994 Jan;41(1):1-52 [8277523.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):8057-61 [14633739.001]
  • [Cites] Ann Med. 2004;36(1):33-40 [15000345.001]
  • [Cites] HNO. 2005 Dec;53(12):1037-46 [15912341.001]
  • [Cites] Chem Biol Interact. 2003 Mar 6;145(1):53-66 [12606154.001]
  • [Cites] Drug Metab Dispos. 1988 May-Jun;16(3):397-402 [2900731.001]
  • [Cites] Toxicology. 2003 Nov 5;192(2-3):171-7 [14580784.001]
  • [Cites] Andrologia. 2004 Oct;36(5):305-10 [15458549.001]
  • [Cites] Chem Res Toxicol. 1998 Jun;11(6):559-603 [9625726.001]
  • [Cites] HNO. 1999 Aug;47(8):684-7 [10506493.001]
  • [Cites] Environ Mol Mutagen. 2000;35(3):206-21 [10737956.001]
  • [Cites] Toxicol Sci. 2004 May;79(1):75-81 [14718647.001]
  • [Cites] Mutat Res. 1996 Feb;367 (2):83-92 [8643119.001]
  • [Cites] HNO. 2003 Feb;51(2):134-9 [12589419.001]
  • [Cites] Crit Rev Oral Biol Med. 2004 Sep 01;15(5):252-63 [15470264.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 1998 Mar;357(3):344-50 [9550308.001]
  • [Cites] Cancer Res. 1993 Feb 15;53(4):733-6 [8381327.001]
  • [Cites] Cancer Lett. 1990 Oct 8;54(1-2):89-94 [2208095.001]
  • [Cites] Mutat Res. 1983 Dec;124(3-4):281-6 [6318103.001]
  • [Cites] Mutat Res. 2004 Jul 11;561(1-2):63-73 [15238231.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Jan;308(1):66-72 [14569062.001]
  • [Cites] Carcinogenesis. 2002 Jun;23(6):907-22 [12082012.001]
  • [Cites] Ann Med. 2003;35(2):94-121 [12795339.001]
  • [Cites] HNO. 2003 Mar;51(3):193-197 [28271240.001]
  • [Cites] Drug Metab Dispos. 2005 Feb;33(2):258-61 [15528319.001]
  • [Cites] Toxicology. 1978 Jul;10(3):207-20 [705796.001]
  • [Cites] HNO. 2005 Feb;53(2):155-62 [15184987.001]
  • [Cites] Carcinogenesis. 2004 Dec;25(12 ):2487-95 [15319299.001]
  • [Cites] FEBS Lett. 2001 Aug 31;504(3):118-25 [11532443.001]
  • [Cites] Drug Metab Rev. 2002 Nov;34(4):865-77 [12487152.001]
  • [Cites] Mol Cells. 2003 Oct 31;16(2):143-6 [14651253.001]
  • [Cites] Carcinogenesis. 1990 Sep;11(9):1663-6 [2205411.001]
  • [Cites] J Clin Invest. 2003 Jan;111(1):31-3 [12511585.001]
  • (PMID = 16170509.001).
  • [ISSN] 0017-6192
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Chewing Gum; 0 / DNA Adducts; 6M3C89ZY6R / Nicotine
  •  go-up   go-down


34. Ahmed S: The culture of neural stem cells. J Cell Biochem; 2009 Jan 1;106(1):1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neural stem cells (NSCs) are present during embryonic development and in certain regions of the adult central nervous system (CNS).
  • Mobilizing adult NSCs to promote repair of injured or diseased CNS is a promising approach.
  • Since NSCs may give rise to brain tumor, they represent in vitro models for anti-cancer drug screening.
  • Important future directions that are highlighted in this review are; identification of markers for NSCs, the use of NSCs in high-throughput screens and the modelling of the central nervous development.
  • There is no doubt that the study of NSCs is crucial if we are to tackle the diseases of the CNS such as Parkinson's and Alzheimer's.
  • [MeSH-minor] Animals. Cells, Cultured. Central Nervous System / cytology. Humans. Models, Biological

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 Wiley-Liss, Inc.
  • (PMID = 19021147.001).
  • [ISSN] 1097-4644
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 80
  •  go-up   go-down


35. Bookland MJ, Bagley CA, Schwarz J, Burger PC, Brem H: Intracavernous trigeminal ganglion amyloidoma: case report. Neurosurgery; 2007 Mar;60(3):E574; discussion E574
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Isolated amyloidomas rarely manifest in nervous system tissues.
  • To the authors' knowledge, there have been 52 documented cases of primary amyloid tumors of the central nervous system and closely associated structures.
  • With the site of the tumor within the cavernous sinus verified by pathology, the remainder of the tumor was removed.
  • A final pathological review of the resected tumor confirmed a diagnosis of amyloidoma of the trigeminal ganglion.
  • Furthermore, central and peripheral nervous system amyloidomas respond well to surgical resection and rarely recur.
  • [MeSH-minor] Adult. Female. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Trigeminal Neuralgia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17327767.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Maier B, Laurer HL, Rose S, Buurman WA, Marzi I: Physiological levels of pro- and anti-inflammatory mediators in cerebrospinal fluid and plasma: a normative study. J Neurotrauma; 2005 Jul;22(7):822-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Numerous recent studies have reported a significant inflammatory reaction in the brain and the systemic circulation following traumatic brain injury (TBI), infection, or neoplasm of the brain with a sequential release of pro- and anti-inflammatory mediators.
  • Pro- and anti-inflammatory mediators exhibited different concentration patterns in plasma and CSF, suggesting a pro-inflammatory predisposition in the central nervous system.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anesthesia, Spinal. Biomarkers / blood. Biomarkers / cerebrospinal fluid. E-Selectin / blood. E-Selectin / cerebrospinal fluid. Female. Humans. Intercellular Adhesion Molecule-1 / blood. Intercellular Adhesion Molecule-1 / cerebrospinal fluid. Interleukins / blood. Interleukins / cerebrospinal fluid. Male. Middle Aged. Orthopedic Procedures. Predictive Value of Tests. Receptors, Tumor Necrosis Factor / blood. Reference Values. Urologic Surgical Procedures

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16004584.001).
  • [ISSN] 0897-7151
  • [Journal-full-title] Journal of neurotrauma
  • [ISO-abbreviation] J. Neurotrauma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / E-Selectin; 0 / Inflammation Mediators; 0 / Interleukins; 0 / Receptors, Tumor Necrosis Factor; 126547-89-5 / Intercellular Adhesion Molecule-1
  •  go-up   go-down


37. Kamnasaran D, Guha A: Expression of GATA6 in the human and mouse central nervous system. Brain Res Dev Brain Res; 2005 Nov 7;160(1):90-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of GATA6 in the human and mouse central nervous system.
  • The expression profile of GATA6 has been poorly defined in the central nervous system (CNS).
  • In this report, we identify GATA6 expression in the normal mouse and human CNS, using Northern blot analyses, immunohistochemistry (IHC), and immunofluorescence (IF).
  • GATA6 is expressed as a 2.2 kb transcript in the adult mouse brain and several regions of the adult human brain.
  • [MeSH-major] Astrocytes / metabolism. Central Nervous System / growth & development. Endothelial Cells / metabolism. GATA6 Transcription Factor / metabolism. Gene Expression Regulation, Developmental / genetics. Neurons / metabolism
  • [MeSH-minor] Aging / genetics. Aging / metabolism. Animals. Animals, Newborn. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Cell Differentiation / genetics. Cell Line. Choroid Plexus / metabolism. Genes, Tumor Suppressor / physiology. Glioma / genetics. Glioma / metabolism. Humans. Immunohistochemistry. Mice. Protein Isoforms / genetics. Protein Isoforms / metabolism. RNA, Messenger / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16150495.001).
  • [ISSN] 0165-3806
  • [Journal-full-title] Brain research. Developmental brain research
  • [ISO-abbreviation] Brain Res. Dev. Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / GATA6 Transcription Factor; 0 / GATA6 protein, human; 0 / Protein Isoforms; 0 / RNA, Messenger
  •  go-up   go-down


38. Bookland M, Anderson WS, Biser-Rohrbaugh A, Jallo GI: Primary pineal malignant melanoma. Pediatr Neurosurg; 2007;43(4):303-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary pineal malignant melanomas are a rare subset of primary central nervous system melanomas.
  • Her treatment consisted of stereotactic radiation to the pineal tumor, conventional whole-brain radiation and Temodar(R) for the disseminated disease.
  • This report details the clinical features of the case and summarizes the literature on a rare but aggressive neoplasm.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Melanoma / diagnosis. Melanoma / therapy. Pineal Gland
  • [MeSH-minor] Adult. Female. Humans

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel.
  • (PMID = 17627147.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


39. Morita S, Oka Y, Tsuboi A, Kawakami M, Maruno M, Izumoto S, Osaki T, Taguchi T, Ueda T, Myoui A, Nishida S, Shirakata T, Ohno S, Oji Y, Aozasa K, Hatazawa J, Udaka K, Yoshikawa H, Yoshimine T, Noguchi S, Kawase I, Nakatsuka S, Sugiyama H, Sakamoto J: A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Jpn J Clin Oncol; 2006 Apr;36(4):231-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data.
  • OBJECTIVE: We conducted a phase I study to investigate the safety of a weekly WT1 tumor vaccine therapy in patients with solid tumors that had been refractory to all other anti-cancer therapies.
  • Moreover, we performed an exploratory assessment of the anti-tumor effects of WT1 treatment.
  • CONCLUSION: This paper confirms that the potential toxicities of the treatment schedule of weekly WT1 vaccination are acceptable and suggested a potential anti-tumor effect.
  • [MeSH-major] Breast Neoplasms / therapy. Cancer Vaccines / therapeutic use. Central Nervous System Neoplasms / therapy. Glioblastoma / therapy. Immunotherapy. WT1 Proteins / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bayes Theorem. Female. Humans. Injections, Intradermal. Male. Middle Aged. Vaccination

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16611662.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / WT1 Proteins
  •  go-up   go-down


40. Leighl NB, Laurie SA, Chen XE, Ellis P, Shepherd FA, Knox JJ, Goss G, Burkes RL, Pond GR, Dick C, Yen Y, Zwiebel JA, Moore MJ: A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium. J Thorac Oncol; 2009 Sep;4(9):1163-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Advanced solid tumor patients, preferably with platinum-treated NSCLC, performance status 0 to 2, no symptomatic central nervous system metastases, adequate organ and bone marrow function, and >or=1 prior chemotherapy regimen were treated with escalating doses of GTI-2040 given by 14-day continuous intravenous infusion (CVI) plus docetaxel every 21 days.
  • One prostate specific antigen response was seen in phase I, but no objective tumor responses in the NSCLC patients.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharm Res. 2006 Jun;23(6):1251-64 [16718617.001]
  • [Cites] Oncol Rep. 2006 May;15(5):1299-304 [16596201.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2095-103 [10811675.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2354-62 [10856094.001]
  • [Cites] Ann Oncol. 2002 Apr;13(4):539-45 [12056703.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1110-7 [15020613.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1589-97 [15117980.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Adv Enzyme Regul. 1988;27:437-55 [3074632.001]
  • [Cites] Crit Rev Oncol Hematol. 1996 Mar;22(2):89-126 [8679103.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4876-81 [9354452.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1650-3 [9563477.001]
  • [Cites] Ann Oncol. 2005 Jun;16(6):958-65 [15824081.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Dec 27;829(1-2):45-9 [16226062.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1428-34 [16549837.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • (PMID = 19704337.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CM / CM062203; United States / NCI NIH HHS / CM / N01 CM062203
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligodeoxyribonucleotides; 0 / Taxoids; 15H5577CQD / docetaxel; 236391-66-5 / GTI2040
  • [Other-IDs] NLM/ NIHMS126881; NLM/ PMC2735463
  •  go-up   go-down


41. Viapiano MS, Bi WL, Piepmeier J, Hockfield S, Matthews RT: Novel tumor-specific isoforms of BEHAB/brevican identified in human malignant gliomas. Cancer Res; 2005 Aug 1;65(15):6726-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel tumor-specific isoforms of BEHAB/brevican identified in human malignant gliomas.
  • Malignant gliomas are deadly brain tumors characterized by diffuse invasion into the surrounding brain tissue.
  • We have previously shown that BEHAB/brevican, an extracellular matrix protein in the central nervous system, plays a role in the invasive ability of gliomas.
  • Here we describe for the first time the expression of BEHAB/brevican in human brain and characterize two novel glioma-specific isoforms, B/b(sia) and B/b(Deltag), which are generated by differential glycosylation and are absent from normal adult brain and other neuropathologies.
  • In addition, its absence from benign gliomas prompts its use as a diagnostic marker to distinguish primary brain tumors of similar histology but different pathologic course.
  • [MeSH-major] Brain Neoplasms / metabolism. Carrier Proteins / metabolism. Glioma / metabolism. Nerve Tissue Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Animals. Brevican. Cell Membrane / metabolism. Chondroitin Sulfate Proteoglycans. Female. Glycosylation. Humans. Lectins, C-Type. Male. Middle Aged. Protein Isoforms. Rats. Transfection

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061654.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01/NS35228
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCAN protein, human; 0 / Brevican; 0 / Carrier Proteins; 0 / Chondroitin Sulfate Proteoglycans; 0 / Lectins, C-Type; 0 / Nerve Tissue Proteins; 0 / Protein Isoforms
  •  go-up   go-down


42. Dusick JR, Esposito F, Kelly DF, Cohan P, DeSalles A, Becker DP, Martin NA: The extended direct endonasal transsphenoidal approach for nonadenomatous suprasellar tumors. J Neurosurg; 2005 May;102(5):832-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The extended direct endonasal transsphenoidal approach for nonadenomatous suprasellar tumors.
  • OBJECT: The extended transsphenoidal approach, which requires a bone and dural opening through the tuberculum sellae and posterior planum sphenoidale, is increasingly used for the treatment of nonadenomatous suprasellar tumors.
  • The authors present their experiences in using the direct endonasal approach in patients with nonadenomatous suprasellar tumors.
  • Twenty-six procedures for tumor removal were performed in 24 patients (ages 9-79 years), including two repeated operations for residual tumor.
  • Of 13 patients with tumor-related visual loss, 85% improved postoperatively.
  • CONCLUSIONS: The direct endonasal skull-base approach provides an effective minimally invasive means for resecting or debulking nonadenomatous suprasellar tumors that have traditionally been approached through a sublabial or transcranial route.
  • [MeSH-major] Brain Neoplasms / surgery. Minimally Invasive Surgical Procedures / methods. Neurosurgical Procedures / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Brain Diseases / surgery. Central Nervous System Cysts / surgery. Child. Craniopharyngioma / surgery. Epidermal Cyst / surgery. Humans. Meningeal Neoplasms / surgery. Meningioma / surgery. Middle Aged. Pituitary Neoplasms / surgery. Postoperative Complications. Sphenoid Bone. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2005 May;102(5):825-7; discussion 827-8 [15926704.001]
  • (PMID = 15926706.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Badruddoja MA, Keir ST, King I, Zeidner J, Vredenburgh JJ, Muhlbaier LH, Bigner DD, Friedman HS: Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice. Neuro Oncol; 2007 Jul;9(3):240-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice.
  • The current study was designed to assess the activity of VNP40101M administered at a dose of 18 mg/kg daily for five days against a panel of human adult and pediatric CNS tumors growing subcutaneously or intracranially in athymic nude mice.
  • The results demonstrated statistically significant (p < 0.05) growth delays of 15.0, 8.3, 51.0, 60+, 60+, and 60+ days in subcutaneous xenografts derived from childhood glioblastoma multiforme (D-456 MG), childhood ependymoma (D-528 EP and D-612 EP), childhood medulloblastoma (D-425 MED), and adult malignant glioma (D-245 MG and D-54 MG), respectively, with corresponding tumor regressions in 10 of 10, 4 of 10, 8 of 10, 9 of 10, 9 of 10, and 10 of 10 treated mice, respectively.
  • Additional experiments conducted against subcutaneous D-245 MG xenografts by using reduced doses of 13.5 or 9.0 mg/kg daily for five days demonstrated tumor growth delays of 82.2 and 53.5 days, with corresponding tumor regressions in 8 of 9 and 9 of 10 treated mice, respectively (all values, p < 0.001), with one toxic death.
  • These findings suggest that VNP40101M is active in the treatment of a wide range of human central nervous system tumors and warrants translation to the clinic.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 1994;34(2):171-4 [8194169.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5368-72 [2164681.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2853-7 [7796412.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):2933-6 [9230204.001]
  • [Cites] Invest New Drugs. 2005 Mar;23(2):123-35 [15744588.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Biochem Pharmacol. 2000 Feb 1;59(3):283-91 [10609557.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3033-8 [11306484.001]
  • [Cites] Int J Toxicol. 2002 Jan-Feb;21(1):23-38 [11936896.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Apr;53(4):288-95 [14685775.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2908-17 [15131024.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Neurosurgery. 1979 Apr;4(4):308-14 [450229.001]
  • [Cites] Cancer Res. 1988 Aug 1;48(15):4189-95 [3390813.001]
  • [Cites] J Neurooncol. 1994;20(2):111-20 [7807189.001]
  • (PMID = 17522334.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / P50 NS020023; United States / NINDS NIH HHS / NS / 5P50-NS20023-23
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hydrazines; 0 / Prodrugs; 0 / Sulfonamides; 14J2G0U3NQ / laromustine
  • [Other-IDs] NLM/ PMC1907418
  •  go-up   go-down


44. Privitera G, Acquaviva G, Ettorre GC, Spatola C: Antiangiogenic therapy in the treatment of recurrent medulloblastoma in the adult: case report and review of the literature. J Oncol; 2009;2009:247873
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiangiogenic therapy in the treatment of recurrent medulloblastoma in the adult: case report and review of the literature.
  • Medulloblastoma is a rare tumor in central nervous system, with an even rarer occurrence in adulthood.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurol. 2005 Mar;252(3):291-9 [16189725.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):832-45 [10071274.001]
  • [Cites] Pediatr Res. 2008 May;63(5):584-90 [18427305.001]
  • [Cites] Neuro Oncol. 2007 Oct;9(4):384-92 [17704359.001]
  • [Cites] Paediatr Drugs. 2007;9(2):81-96 [17407364.001]
  • [Cites] J Neurooncol. 1997 Nov;35(2):169-76 [9266455.001]
  • [Cites] J Neurosurg. 1994 Nov;81(5):690-8 [7931615.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):433-40 [1847194.001]
  • [Cites] Cancer. 1990 Dec 15;66(12):2465-9 [2249186.001]
  • [Cites] Eur J Cancer. 1990 Apr;26(4):464-9 [2141512.001]
  • [Cites] J Neurosurg. 1990 Apr;72(4):572-82 [2319316.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1581-91 [12697884.001]
  • (PMID = 20111585.001).
  • [ISSN] 1687-8469
  • [Journal-full-title] Journal of oncology
  • [ISO-abbreviation] J Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2804042
  •  go-up   go-down


45. Grunberg SM, Weiss MH, Russell CA, Spitz IM, Ahmadi J, Sadun A, Sitruk-Ware R: Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest; 2006 Dec;24(8):727-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, treatment of neoplasms or chronic conditions will require long-term administration.
  • Meningioma is a benign central nervous system tumor that is often progesterone-but not estrogen-receptor positive, making long-term antiprogestational therapy a logical treatment strategy.
  • Serial follow-up allowed evaluation for tolerability and side effects of long-term therapy as well as observation for efficacy (tumor shrinkage or improvement in visual fields).
  • [MeSH-major] Contraceptives, Oral, Synthetic / administration & dosage. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy. Mifepristone / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MIFEPRISTONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17162554.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2P30 CA14089
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contraceptives, Oral, Synthetic; 320T6RNW1F / Mifepristone
  •  go-up   go-down


46. De Tommasi A, De Tommasi C, Occhiogrosso G, Cimmino A, Parisi M, Sanguedolce F, Ciappetta P: Primary intramedullary primitive neuroectodermal tumor (PNET)--case report and review of the literature. Eur J Neurol; 2006 Mar;13(3):240-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intramedullary primitive neuroectodermal tumor (PNET)--case report and review of the literature.
  • Spinal primitive neuroectodermal tumors (PNET) are very rare tumors, and intramedullary localization is even less common.
  • Following the WHO 2000 classification, PNETs have been considered embryonal tumors composed of undifferentiated neuroepithelial cells with a capacity of differentiation into different cellular lines, such as astrocytic, ependymal, melanotic and muscular.
  • They have been considered to arise from a neoplastic transformation of primitive neuroepithelial cells, thereby making their presence possible in any part of the central nervous system.
  • The optimal treatment for these malignant tumors is not yet clear, although, over the years, radiotherapy has been considered the best treatment for spinal PNETs.
  • The patient, 18 months after the onset of his symptomatology, died without cerebral tumor involvement.
  • [MeSH-major] Brain Neoplasms. Laminectomy / methods. Neuroectodermal Tumors, Primitive
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618339.001).
  • [ISSN] 1351-5101
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 25
  •  go-up   go-down


47. McKee JA, Brewer RP, Macy GE, Phillips-Bute B, Campbell KA, Borel CO, Reynolds JD, Warner DS: Analysis of the brain bioavailability of peripherally administered magnesium sulfate: A study in humans with acute brain injury undergoing prolonged induced hypermagnesemia. Crit Care Med; 2005 Mar;33(3):661-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS: Thirty patients with acute brain injury secondary to subarachnoid hemorrhage, traumatic brain injury, primary intracerebral hemorrhage, subdural hematoma, brain tumor, central nervous system infection, or ischemic stroke were studied.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biological Availability. Female. Humans. Infusions, Intravenous. Male. Middle Aged

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MAGNESIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. MAGNESIUM SULFATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Crit Care Med. 2005 Mar;33(3):698-9 [15753782.001]
  • (PMID = 15753761.001).
  • [ISSN] 0090-3493
  • [Journal-full-title] Critical care medicine
  • [ISO-abbreviation] Crit. Care Med.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neuroprotective Agents; 7487-88-9 / Magnesium Sulfate; I38ZP9992A / Magnesium
  •  go-up   go-down


48. Santarpia L, Lapa D, Benvenga S: Germline mutation of von Hippel-Lindau (VHL) gene 695 G&gt;A (R161Q) in a patient with a peculiar phenotype with type 2C VHL syndrome. Ann N Y Acad Sci; 2006 Aug;1073:198-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • VHL has intrafamilial variability expression and it is characterized by the predisposition to develop hemangioblastomas of the central nervous system and retina, pheochromocytomas, clear-cell renal carcinoma, adenomas, and carcinomas of the pancreas, paragangliomas, renal and pancreatic cysts, papillary cystadenomas of the epididymis and, rarely, cystadenomas of the endolymphatic sac tumor and broad ligament.
  • [MeSH-major] Germ-Line Mutation. Von Hippel-Lindau Tumor Suppressor Protein / genetics. von Hippel-Lindau Disease / genetics
  • [MeSH-minor] Adult. Humans. Phenotype

  • Genetic Alliance. consumer health - Von Hippel-Lindau syndrome.
  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17102087.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  •  go-up   go-down


49. Zhang SJ, Endo S, Saito T, Kouno M, Kuroiwa T, Washiyama K, Kumanishi T: Primary malignant lymphoma of the brain: frequent abnormalities and inactivation of p14 tumor suppressor gene. Cancer Sci; 2005 Jan;96(1):38-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant lymphoma of the brain: frequent abnormalities and inactivation of p14 tumor suppressor gene.
  • Ten primary central nervous system lymphomas (PCNSL, brain lymphomas) were examined for p14 gene exon 1beta deletion, mutation and methylation by Southern blot analysis, nucleotide analysis of polymerase chain reaction clones and Southern blot-based methylation assay.
  • In addition, although exon 1beta mutation is rare in various tumors, we detected a missense mutation (L50R) in one case with a hemizygous deletion.
  • [MeSH-major] Brain Neoplasms / genetics. Genes, Tumor Suppressor. Lymphoma / genetics. Tumor Suppressor Protein p14ARF / genetics
  • [MeSH-minor] Adult. Aged. Base Sequence. Blotting, Southern. DNA Methylation. Female. Humans. Male. Middle Aged. Mutation


50. Doolittle ND, Jahnke K, Belanger R, Ryan DA, Nance RW Jr, Lacy CA, Tyson RM, Haluska M, Hedrick NA, Varallyay C, Neuwelt EA: Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma. Leuk Lymphoma; 2007 Sep;48(9):1712-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma.
  • There was good uptake of Indium-111 ibritumomab tiuxetan in tumor on SPECT scan after 48 h.
  • Estimated radiation doses to brain around and distant from tumor were within safe limits.
  • After Ytrium-90 ibritumomab tiuxetan there was CR in enhancing tumor where the BBB was leaky, but lesions occurred in other brain regions, where the BBB was intact during Yttrium-90 ibritumomab tiuxetan infusion.
  • Imaging and dosimetry with Indium-111 ibritumomab tiuxetan and efficacy with Yttrium-90 ibritumomab tiuxetan suggest the need for future enhanced CNS delivery when using monoclonal or radiolabeled antibodies, as intravenous delivery alone may provide modest clinical benefit due to limited BBB permeability.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Brain Neoplasms / therapy. Lymphoma, Non-Hodgkin / therapy. Radioimmunotherapy. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Adult. Aged. Blood-Brain Barrier. Carboplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Indium Radioisotopes / therapeutic use. Male. Methotrexate / administration & dosage. Middle Aged

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17786706.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS33618; United States / NINDS NIH HHS / NS / NS34608; United States / NINDS NIH HHS / NS / NS44687
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Indium Radioisotopes; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan; BG3F62OND5 / Carboplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


51. Galli R, Gritti A, Vescovi AL: Adult neural stem cells. Methods Mol Biol; 2008;438:67-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult neural stem cells.
  • Neural stem cells (NSCs) have been identified in the mature central nervous system (CNS), and they reside in specific areas.
  • The proper application of this method to the cells allows the establishment of long-term expanding stable NSC lines, starting from different neural tissues as the adult rodent CNS and human brain tumor specimens.
  • [MeSH-minor] Animals. Cell Differentiation. Cell Separation. Cells, Cultured. Central Nervous System / cytology. Central Nervous System / pathology. Dissection. Humans. Neoplastic Stem Cells / cytology. Rodentia

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18369750.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Inci S, Bozkurt G, Gulsen S, Firat P, Ozgen T: Rare cause of subarachnoid hemorrhage: spinal meningeal carcinomatosis. Case report. J Neurosurg Spine; 2005 Jan;2(1):79-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although primary spinal tumors, especially ependymomas, are also relatively common causes, SAH secondary to a metastatic spinal tumor arising from outside the central nervous system is an extremely rare condition; only one case has been reported in the literature.
  • [MeSH-major] Carcinoma / complications. Melanoma / secondary. Meningeal Neoplasms / complications. Skin Neoplasms / pathology. Spinal Neoplasms / complications. Subarachnoid Hemorrhage / etiology
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15658132.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Iłzecka J: Decreased serum-soluble TRAIL levels in patients with amyotrophic lateral sclerosis. Acta Neurol Scand; 2008 May;117(5):343-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a cytokine with proapoptotic activity in the central nervous system.
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Enzyme-Linked Immunosorbent Assay / methods. Female. Humans. Male. Middle Aged. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Amyotrophic Lateral Sclerosis.
  • MedlinePlus Health Information. consumer health - Amyotrophic Lateral Sclerosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17995989.001).
  • [ISSN] 1600-0404
  • [Journal-full-title] Acta neurologica Scandinavica
  • [ISO-abbreviation] Acta Neurol. Scand.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human
  •  go-up   go-down


54. Metellus P, Bouvier C, Guyotat J, Fuentes S, Jouvet A, Vasiljevic A, Giorgi R, Dufour H, Grisoli F, Figarella-Branger D: Solitary fibrous tumors of the central nervous system: clinicopathological and therapeutic considerations of 18 cases. Neurosurgery; 2007 Apr;60(4):715-22; discussion 722
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumors of the central nervous system: clinicopathological and therapeutic considerations of 18 cases.
  • OBJECTIVE: This is a retrospective study of 18 patients harboring a solitary fibrous tumor of the central nervous system.
  • METHODS: Between 1999 and 2004, 18 patients harboring central nervous system solitary fibrous tumors were surgically treated at our two institutions.
  • Gross total resection was achieved in 10 cases (55.6%); tumor recurrence or progression occurred in nine cases (50%).
  • CONCLUSION: Prognosis of solitary fibrous tumors of the central nervous system remains unclear; consequently, careful and close monitoring of patients and long-term follow-up are mandatory.
  • In other respects, the role of postoperative radiotherapy in atypical or incompletely resected solitary fibrous tumors of the central nervous system remains to be determined and, therefore, warrants larger series with longer follow-up periods.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Neoplasms, Fibrous Tissue / radiotherapy. Neoplasms, Fibrous Tissue / surgery. Spinal Neoplasms / radiotherapy. Spinal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17415209.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Wilms H, Schwark T, Brandenburg LO, Sievers J, Dengler R, Deuschl G, Lucius R: Regulation of activin A synthesis in microglial cells: pathophysiological implications for bacterial meningitis. J Neurosci Res; 2010 Jan;88(1):16-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, to elucidate further the functional significance and pathophysiological implications of these findings, we demonstrated that microglial cells are not only the source but also the target cells of activin A in the central nervous system: immunohistochemistry and RT-PCR revealed expression of activin subunit betaA mRNA as well as activin receptor type I and type II mRNA in rat microglia in vitro.
  • Furthermore, quantitative RT-PCR, Western blotting, and ELISA showed an inhibitory effect of activin on inducible nitric oxide synthase, tumor necrosis factor-alpha, interleukin-6, and interleukin-1beta gene and protein levels after lipopolysaccharide treatment.
  • [MeSH-minor] Activin Receptors / genetics. Activin Receptors / metabolism. Adolescent. Adult. Aged. Aged, 80 and over. Analysis of Variance. Animals. Blotting, Western. Cell Proliferation. Cells, Cultured. Cytokines / genetics. Cytokines / metabolism. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. Interferon-gamma / pharmacology. Lipopolysaccharides / pharmacology. Male. Meningitis, Viral / genetics. Meningitis, Viral / metabolism. Middle Aged. Nitric Oxide Synthase Type II / genetics. Nitric Oxide Synthase Type II / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Rats. Rats, Wistar. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Bacterial Meningitis.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19681171.001).
  • [ISSN] 1097-4547
  • [Journal-full-title] Journal of neuroscience research
  • [ISO-abbreviation] J. Neurosci. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Lipopolysaccharides; 0 / RNA, Messenger; 0 / activin A; 104625-48-1 / Activins; 82115-62-6 / Interferon-gamma; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 2.7.11.30 / Activin Receptors
  •  go-up   go-down


56. Jounieaux F, Chapelon C, Valeyre D, Israel Biet D, Cottin V, Tazi A, Fournier E, Wallaert B, Groupe sarcoïdose francophone de la SPLF: [Infliximab treatment for chronic sarcoidosis--a case series]. Rev Mal Respir; 2010 Sep;27(7):685-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A beneficial response to infliximab was observed in 62% of the cases across all organs involved: 65% for lung involvement, 67% for skin lesions and 50% for central nervous system lesions.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • [MeSH-minor] Adult. Chronic Disease. Female. Humans. Infliximab. Male. Middle Aged. Retrospective Studies. Sarcoidosis, Pulmonary

  • Genetic Alliance. consumer health - Sarcoidosis.
  • Hazardous Substances Data Bank. Infliximab .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 SPLF. Published by Elsevier Masson SAS. All rights reserved.
  • (PMID = 20863968.001).
  • [ISSN] 1776-2588
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab
  •  go-up   go-down


57. Crawford JR, Santi MR, Cornelison R, Sallinen SL, Haapasalo H, MacDonald TJ: Detection of human herpesvirus-6 in adult central nervous system tumors: predominance of early and late viral antigens in glial tumors. J Neurooncol; 2009 Oct;95(1):49-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of human herpesvirus-6 in adult central nervous system tumors: predominance of early and late viral antigens in glial tumors.
  • The purpose is to determine the incidence of active and latent human herpesvirus-6 (HHV-6) infection in a large cohort of adult primary and recurrent CNS tumors.
  • We screened a tissue microarray (TMA) containing more than 200 adult primary and recurrent CNS tumors with known clinical information for the presence of HHV-6 DNA by in situ hybridization (ISH) and protein by immunohistochemistry (IHC).
  • One hundred six of 224 (47%) CNS tumors were positive for HHV-6 U57 Major Capsid Protein (MCP) gene by ISH compared to 0/25 non tumor control brain (P = 0.001).
  • Fourteen of 30 (47%) tumors were HHV-6 MCP positive by nested PCR compared to 0/25 non-tumor brain controls (P = 0.001), revealing HHV-6 Variant A in 6 of 14 samples.
  • HHV-6A/B early (p41) and late (gp116/64/54) antigens were detected by IHC in 66 of 277 (24%) (P = 0.003) and 84 of 282 (35%) (P = 0.002) tumors, respectively, suggesting active infection.
  • Glial tumors were 3 times more positive by IHC compared to non glial tumors for both HHV-6 gp116/64/54 (P = 0.0002) and HHV-6 p41 (P = 0.004).
  • HHV-6 early and late antigens are detected in adult primary and recurrent CNS tumors more frequently in glial tumors.
  • We hypothesize that the glial-tropic features of HHV-6 may play an important modifying role in tumor biology that warrants further investigation.
  • [MeSH-major] Antigens, Viral. Central Nervous System Neoplasms / genetics. Central Nervous System Neoplasms / virology. Glioma / genetics. Glioma / virology. Herpesvirus 6, Human / isolation & purification
  • [MeSH-minor] Adult. Antigens, CD / metabolism. CD48 Antigen. Capsid Proteins / genetics. Capsid Proteins / metabolism. Humans. Survival Analysis. Viral Envelope Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1988 May 14;1(8594):1065-7 [2896909.001]
  • [Cites] J Pathol. 2002 Jul;197(3):395-402 [12115887.001]
  • [Cites] Clin Microbiol Rev. 1999 Jul;12(3):367-82 [10398670.001]
  • [Cites] J Infect Dis. 2000 Nov;182(5):1321-5 [11023456.001]
  • [Cites] J Med Virol. 2005 Jan;75(1):76-85 [15543581.001]
  • [Cites] Neurology. 2003 Nov 25;61(10):1405-11 [14638964.001]
  • [Cites] J Med Virol. 2007 Jan;79(1):45-51 [17133548.001]
  • [Cites] J Virol. 2005 Aug;79(15):9439-48 [16014907.001]
  • [Cites] Pediatrics. 2008 Sep;122(3):513-20 [18762520.001]
  • [Cites] Mult Scler. 2004 Aug;10(4):355-9 [15327029.001]
  • [Cites] J Infect Dis. 2003 May 1;187(9):1377-87 [12717618.001]
  • [Cites] Curr Infect Dis Rep. 2008 Jul;10(4):292-9 [18765102.001]
  • [Cites] Curr Infect Dis Rep. 2004 Aug;6(4):316-321 [15265461.001]
  • [Cites] Blood. 1999 Sep 1;94(5):1545-9 [10477678.001]
  • [Cites] PLoS One. 2008 Apr 30;3(4):e2028 [18446218.001]
  • [Cites] Oncogene. 1997 Jan 23;14(3):359-67 [9018122.001]
  • [Cites] Epilepsia. 2008 Nov;49(11):1828-37 [18627418.001]
  • [Cites] Bone Marrow Transplant. 2007 Sep;40(6):563-6 [17637686.001]
  • [Cites] Annu Rev Med. 2000;51:423-30 [10774474.001]
  • [Cites] New Microbiol. 1999 Oct;22(4):293-300 [10555198.001]
  • [Cites] J Neurosci. 2004 May 19;24(20):4875-83 [15152048.001]
  • [Cites] Mult Scler. 1999 Oct;5(5):355-62 [10516780.001]
  • [Cites] J Neurovirol. 2003 Oct;9(5):539-50 [13129768.001]
  • [Cites] J Neurol Sci. 1995 Dec;134(1-2):184-8 [8747864.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6617-22 [11118044.001]
  • [Cites] Neuro Oncol. 2008 Feb;10(1):10-8 [17951512.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):539-41 [18669440.001]
  • [Cites] J Child Neurol. 2007 Nov;22(11):1260-8 [18006954.001]
  • [Cites] J Neurovirol. 1998 Oct;4(5):486-94 [9839646.001]
  • [Cites] Acta Neuropathol. 2008 Jul;116(1):79-86 [18351367.001]
  • [Cites] Clin Diagn Virol. 1996 Jun;6(1):33-40 [15566888.001]
  • [Cites] Glia. 2006 Jun;53(8):789-98 [16541415.001]
  • [Cites] J Med Virol. 2008 Apr;80(4):689-93 [18297709.001]
  • [Cites] J Med Virol. 2004 Jul;73(3):465-73 [15170644.001]
  • [Cites] Hematol Oncol. 2004 Dec;22(4):169-77 [16134192.001]
  • [Cites] J Neurol. 1997 Jul;244(7):450-4 [9266465.001]
  • [Cites] J Clin Pathol. 1999 Aug;52(8):620-3 [10645234.001]
  • [Cites] J Clin Microbiol. 2008 Aug;46(8):2700-6 [18550745.001]
  • [Cites] J Med Virol. 2001 Jan;63(1):45-51 [11130886.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):838-43 [15578071.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3347-50 [12067971.001]
  • [Cites] Brain Res. 2008 Jul 24;1221:108-14 [18565499.001]
  • [Cites] Clin Microbiol Rev. 2005 Jan;18(1):217-45 [15653828.001]
  • [Cites] J Med Virol. 1995 Sep;47(1):105-11 [8551252.001]
  • [Cites] J Med Microbiol. 2003 Jan;52(Pt 1):5-18 [12488560.001]
  • [Cites] J Infect Dis. 2006 Apr 1;193(7):912-6 [16518751.001]
  • [Cites] J Infect Dis. 2007 Feb 1;195(3):450-4 [17205485.001]
  • [Cites] J Neurovirol. 2006 Apr;12(2):90-9 [16798670.001]
  • [Cites] PLoS Med. 2007 May;4(5):e180 [17535102.001]
  • (PMID = 19424665.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / K12NS052159-01A
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Viral; 0 / CD48 Antigen; 0 / Capsid Proteins; 0 / Viral Envelope Proteins
  •  go-up   go-down


58. Kimura N, Yamamoto Y, Kameyama R, Hatakeyama T, Kawai N, Nishiyama Y: Diagnostic value of kinetic analysis using dynamic 18F-FDG-PET in patients with malignant primary brain tumor. Nucl Med Commun; 2009 Aug;30(8):602-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of kinetic analysis using dynamic 18F-FDG-PET in patients with malignant primary brain tumor.
  • OBJECTIVE: The purpose of this study was to evaluate the efficacy of quantitative imaging of glucose metabolism with positron emission tomography (PET) using kinetic analysis for differentiating between high-grade glioma and central nervous system (CNS) lymphoma.
  • METHODS: Dynamic fluorine-18-fluorodeoxyglucose (18F-FDG)-PET scans obtained in 20 patients with high-grade glioma (World Health Organization grade III, five lesions; grade IV, 15 lesions) and in 12 patients with CNS lymphoma (16 lesions) were retrospectively reviewed.
  • Fourteen CNS lymphoma lesions showed an increase of K1, 16 of k3, two of k4, and 14 of CMR(Glc).
  • Both k3 and CMR(Glc) values (mean+/-SD) of CNS lymphoma (0.096+/-0.046 and 77.4+/-37.7, respectively) were significantly higher than those of the normal gray matter (0.059+/-0.015 and 41.3+/-9.3, respectively; P<0.007 and P<0.002, respectively).
  • The k3 value of CNS lymphoma was significantly higher than that of grade III (0.058+/-0.022) and grade IV (0.065+/-0.024) gliomas (P<0.03 and P<0.04, respectively).
  • The CMR(Glc) value of CNS lymphoma was significantly higher than that of grade III (33.8+/-7.8) and grade IV (41.5+/-23.1) gliomas (P<0.001 and P<0.004, respectively).
  • The value of k2 of CNS lymphoma was significantly lower than that of grade IV glioma (P<0.05).
  • CONCLUSION: The direct measurement of the regional rate constants by kinetic analysis might be useful for the delineation of CNS lymphoma and for differential diagnosis of high-grade glioma and CNS lymphoma.
  • [MeSH-major] Brain Neoplasms / metabolism. Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Glucose / metabolism
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Glioma / metabolism. Glioma / radionuclide imaging. Humans. Kinetics. Lymphoma / metabolism. Lymphoma / radionuclide imaging. Magnetic Resonance Imaging. Male. Middle Aged. Positron-Emission Tomography. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19521265.001).
  • [ISSN] 1473-5628
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18; IY9XDZ35W2 / Glucose
  •  go-up   go-down


59. Oba-Shinjo SM, Caballero OL, Jungbluth AA, Rosemberg S, Old LJ, Simpson AJ, Marie SK: Cancer-testis (CT) antigen expression in medulloblastoma. Cancer Immun; 2008;8:7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Medulloblastoma is the most common childhood malignant tumor of the central nervous system.
  • Due to their presence in various cancers and their limited expression in normal tissues, CT antigens are ideal vaccine targets for tumor immunotherapy.
  • The absence of correlation between mRNA and protein expression in medulloblastoma has not been observed in other tumors and further studies addressing the biology of CT antigens are necessary to investigate the present discrepant results.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Cerebellar Neoplasms / immunology. Medulloblastoma / immunology
  • [MeSH-minor] Adult. Cancer Vaccines. Child. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Membrane Proteins / biosynthesis. Membrane Proteins / genetics. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. RNA Processing, Post-Transcriptional / genetics. RNA, Messenger / metabolism. Testis / metabolism. Testis / pathology

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Immunol. 2006;24:175-208 [16551247.001]
  • [Cites] Int J Cancer. 2006 Feb 1;118(3):696-703 [16094643.001]
  • [Cites] Int J Oncol. 2006 May;28(5):1089-98 [16596224.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5442-7 [17000678.001]
  • [Cites] Lancet Oncol. 2006 Oct;7(10):813-20 [17012043.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):67-74 [17019710.001]
  • [Cites] Cancer Biol Ther. 2006 Sep;5(9):1218-25 [16929165.001]
  • [Cites] Int J Cancer. 2007 Jan 15;120(2):337-43 [17066423.001]
  • [Cites] Childs Nerv Syst. 2007 Apr;23(4):399-405 [17119978.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2411-7 [17294444.001]
  • [Cites] Int J Cancer. 2000 Mar 1;85(5):726-32 [10699956.001]
  • [Cites] Br J Cancer. 2000 Aug;83(4):493-7 [10945497.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3916-22 [11051238.001]
  • [Cites] Int J Cancer. 2001 May 1;92(3):441-50 [11291084.001]
  • [Cites] Int J Cancer. 2001 Jun 15;92(6):856-60 [11351307.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4809-14 [11406556.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):713-20 [11531257.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6682-7 [11559535.001]
  • [Cites] Int J Cancer. 2002 Jun 20;99(6):839-45 [12115486.001]
  • [Cites] Cancer Biol Ther. 2002 Jul-Aug;1(4):380-7 [12432251.001]
  • [Cites] In Vivo. 2002 Nov-Dec;16(6):583-8 [12494904.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):167-73 [12538465.001]
  • [Cites] Cancer Immun. 2001 Mar 30;1:1 [12747762.001]
  • [Cites] Cancer Immun. 2002 Sep 19;2:11 [12747756.001]
  • [Cites] Lab Invest. 2003 Aug;83(8):1185-92 [12920247.001]
  • [Cites] Brain Pathol. 2003 Jul;13(3):376-85 [12946027.001]
  • [Cites] Cancer Immun. 2004 Jan 23;4:1 [14738373.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):568-75 [14991579.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):698-702 [14999777.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4980-6 [15256472.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10697-702 [15252201.001]
  • [Cites] Science. 1991 Dec 13;254(5038):1643-7 [1840703.001]
  • [Cites] Int J Cancer. 1993 May 28;54(3):527-8 [8509230.001]
  • [Cites] Int J Cancer. 1995 Nov 3;63(3):375-80 [7591235.001]
  • [Cites] Int J Cancer. 1996 Oct 21;69(5):403-7 [8900375.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1914-8 [9050879.001]
  • [Cites] Am J Pathol. 1997 Jun;150(6):2143-52 [9176405.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):743-52 [9485030.001]
  • [Cites] Nat Med. 1998 Mar;4(3):321-7 [9500606.001]
  • [Cites] Nat Med. 1998 Mar;4(3):328-32 [9500607.001]
  • [Cites] Childs Nerv Syst. 1998 Jun;14(6):256-62 [9694337.001]
  • [Cites] Int J Cancer. 1999 Jan 18;80(2):219-30 [9935203.001]
  • [Cites] Clin Cancer Res. 1999 Feb;5(2):335-41 [10037183.001]
  • [Cites] Cancer Immun. 2004 Nov 17;4:13 [15546177.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):119-26 [15272278.001]
  • [Cites] Neurosci Lett. 2005 Jun 10-17;381(1-2):69-73 [15882792.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):615-25 [16034368.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8055-62 [16299236.001]
  • [Cites] Cancer Immun. 2006;6:7 [16594646.001]
  • (PMID = 18426187.001).
  • [ISSN] 1424-9634
  • [Journal-full-title] Cancer immunity
  • [ISO-abbreviation] Cancer Immun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / CTAG1B protein, human; 0 / Cancer Vaccines; 0 / MAGEA3 protein, human; 0 / MAGEC1 protein, human; 0 / MAGEC2 protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2935780
  •  go-up   go-down


60. Samii M, Nakamura M, Mirzai S, Vorkapic P, Cervio A: Cavernous angiomas within the internal auditory canal. J Neurosurg; 2006 Oct;105(4):581-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four patients also reported facial symptoms such as hemispasm or progressive palsy; one of these patients had presented with sudden facial paresis due to intrameatal tumor hemorrhage.
  • The cochlear nerve could not be functionally preserved because of its extreme adherence to the tumor, although its continuity was preserved in four patients.
  • [MeSH-major] Ear Neoplasms / surgery. Hemangioma, Cavernous, Central Nervous System / surgery. Labyrinth Diseases / surgery
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Hearing Loss, Sensorineural / etiology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Postoperative Complications / etiology. Retrospective Studies. Tinnitus / etiology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17044562.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 47
  •  go-up   go-down


61. Gessi M, Legnani FG, Maderna E, Casali C, Solero CL, Pollo B, DiMeco F: Mucinous low-grade adenocarcinoma arising in an intracranial enterogenous cyst: case report. Neurosurgery; 2008 Apr;62(4):E972-3; discussion E973
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Enterogenous cysts (ECs) of the central nervous system are developmental malformations that occur in the spinal canal, posterior fossa, or cerebral hemispheres.
  • Subsequent follow-up computed tomographic scans showed progression of the residual tumor.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / surgery. Brain Neoplasms / diagnosis. Brain Neoplasms / surgery. Cysts / diagnosis. Cysts / surgery. Ventriculoperitoneal Shunt
  • [MeSH-minor] Adult. Humans. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18496166.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Henderson FC, McCool K, Seigle J, Jean W, Harter W, Gagnon GJ: Treatment of chordomas with CyberKnife: georgetown university experience and treatment recommendations. Neurosurgery; 2009 Feb;64(2 Suppl):A44-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Forty-four percent of the tumors were located in the mobile spine, 39% inside the cranium, and 17% in the sacral region.
  • The mean tumor volume was 128.0 mL (range, 12.0-457.3 mL), and the median dose of 35 Gy (range, 24.0-40.0 Gy) was delivered in 5 sessions.
  • CK/SRS appears to reduce tumor volume, given an adequate dose.
  • The authors recommend treatment with 40 Gy in 5 sessions to the clinical treatment volume, which includes the gross tumor volume and at least a 1-cm margin.
  • [MeSH-major] Central Nervous System Neoplasms / surgery. Chordoma / surgery. Radiosurgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose Fractionation. Female. Humans. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Pain / surgery. Postoperative Complications. Quality of Life. Treatment Outcome. Universities

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19165073.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Oishi M, Sasaki O, Nakazato S, Suzuki K, Kitazawa K, Takao T, Koike T: Unusual giant cerebral venous varix associated with brain abscess: variant of hereditary hemorrhagic telangiectasia--case report. Neurol Med Chir (Tokyo); 2007 Feb;47(2):74-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuroimaging incidentally revealed another tumor-like lesion.
  • [MeSH-major] Brain / blood supply. Brain Abscess / complications. Central Nervous System Vascular Malformations / etiology. Intracranial Arteriovenous Malformations / etiology. Telangiectasia, Hereditary Hemorrhagic / complications. Varicose Veins / etiology
  • [MeSH-minor] Adult. Humans. Male

  • Genetic Alliance. consumer health - Hereditary Hemorrhagic Telangiectasia.
  • MedlinePlus Health Information. consumer health - Varicose Veins.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317945.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


64. Tchirkov A, Sapin V, Marceau G, Chautard E, Narla G, Veronese L, Friedman S, Khalil T, Vago P, Kemeny JL, Verrelle P: Increased expression of the oncogenic KLF6-SV1 transcript in human glioblastoma. Clin Chem Lab Med; 2010 Aug;48(8):1167-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Gliomas constitute the vast majority of primary central nervous system tumors in adults.
  • Glioblastoma multiforme (GBM) is the most aggressive form of these primary brain tumors.
  • There is a need to define diagnostic and prognostic markers that may help to distinguish GBM from non-GBM tumors.
  • METHODS: Fifty-three primary gliomas tumor samples were analyzed using quantitative real-time PCR for the total KLF6, wild-type and alternatively spliced (SV1) KLF6 mRNA.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20545576.001).
  • [ISSN] 1437-4331
  • [Journal-full-title] Clinical chemistry and laboratory medicine
  • [ISO-abbreviation] Clin. Chem. Lab. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Carcinogens; 0 / KLF6 protein, human; 0 / Kruppel-Like Transcription Factors; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger
  •  go-up   go-down


65. Lepore AC, Neuhuber B, Connors TM, Han SS, Liu Y, Daniels MP, Rao MS, Fischer I: Long-term fate of neural precursor cells following transplantation into developing and adult CNS. Neuroscience; 2006 Sep 29;142(1):287-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term fate of neural precursor cells following transplantation into developing and adult CNS.
  • Successful strategies for transplantation of neural precursor cells for replacement of lost or dysfunctional CNS cells require long-term survival of grafted cells and integration with the host system, potentially for the life of the recipient.
  • Few studies have examined the long-term properties of transplanted neural precursor cells in the CNS, particularly in non-neurogenic regions of the adult.
  • The aim of the present study was to extensively characterize the fate of defined populations of neural precursor cells following transplantation into the developing and adult CNS (brain and spinal cord) for up to 15 months, including integration of graft-derived neurons with the host.
  • We found that in both developing and adult CNS grafted cells showed long-term survival, morphological maturation, extensive distribution and differentiation into all mature CNS cell types (neurons, astrocytes and oligodendrocytes).
  • Graft-derived neurons also formed synapses, as identified by electron microscopy, suggesting that transplanted neural precursor cells integrated with adult CNS.
  • We did not detect tumor formation, cells did not localize to unwanted locations and no pronounced immune response was present at the graft sites.
  • The long-term stability of neuronal-restricted precursors and glial-restricted precursors and the lack of adverse effects suggest that transplantation of lineage-restricted neural precursor cells can serve as an effective and safe replacement therapy for CNS injury and degeneration.
  • [MeSH-major] Cell Differentiation / physiology. Central Nervous System / physiology. Neurons / physiology. Stem Cell Transplantation / methods. Stem Cells / physiology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RepublishedFrom] Neuroscience. 2006 May 12;139(2):513-30 [16458439.001]
  • (PMID = 17120358.001).
  • [ISSN] 0306-4522
  • [Journal-full-title] Neuroscience
  • [ISO-abbreviation] Neuroscience
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS 37515; United States / NINDS NIH HHS / NS / NS24707
  • [Publication-type] Comparative Study; Corrected and Republished Article; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gangliosides; 0 / Immunosuppressive Agents; 0 / Nerve Tissue Proteins; 0 / Neural Cell Adhesion Molecules; 0 / ganglioside A2B5
  •  go-up   go-down


66. Mei K, Liu A, Allan RW, Wang P, Lane Z, Abel TW, Wei L, Cheng H, Guo S, Peng Y, Rakheja D, Wang M, Ma J, Rodriguez MM, Li J, Cao D: Diagnostic utility of SALL4 in primary germ cell tumors of the central nervous system: a study of 77 cases. Mod Pathol; 2009 Dec;22(12):1628-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic utility of SALL4 in primary germ cell tumors of the central nervous system: a study of 77 cases.
  • Primary germ cell tumors of the central nervous system (CNS) sometimes pose diagnostic difficulty.
  • In this study we analyzed the diagnostic utility of a novel marker, SALL4, in 77 such tumors (59 pure and 18 mixed) consisting of the following tumors/tumor components: 49 germinomas, 7 embryonal carcinomas, 27 yolk sac tumors, 3 choriocarcinomas, and 14 teratomas.
  • We also stained SALL4 in 99 primary non-germ cell tumors to test SALL4 specificity.
  • We compared SALL4 with OCT4 in all germ cell tumors and compared SALL4 with alpha-fetoprotein and glypican-3 in all yolk sac tumors.
  • Strong SALL4 staining was observed in all 49 germinomas (4+ in 48, 3+ in 1), 7 embryonal carcinomas (all 4+), and 27 yolk sac tumors (1+ in 1, 2+ in 2, 3+ in 7, 4+ in 17).
  • All germinomas and embryonal carcinomas showed strong OCT4 staining (4+ in all except 1 germinoma with 3+), whereas other germ cell tumors were negative.
  • Out of 27 yolk sac tumors, 26 showed positive alpha-fetoprotein staining (1+ in 9, 2+ in 7, 3+ in 5, and 4+ in 5).
  • All yolk sac tumors showed positive glypican-3 staining (1+ in 6, 2+ in 6, 3+ in 7, and 4+ in 8).
  • The mean percentage of yolk sac tumor cells stained was 84% with SALL4, 45% with alpha-fetoprotein, and 63% with glypican-3 (P<0.01).
  • No non-germ cell tumors showed SALL4 staining.
  • Our results indicate that SALL4 is a novel sensitive diagnostic marker for primary germ cell tumors of the CNS with high specificity.
  • SALL4 is a more sensitive marker than alpha-fetoprotein and glypican-3 for yolk sac tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Central Nervous System Neoplasms / chemistry. Neoplasms, Germ Cell and Embryonal / chemistry. Transcription Factors / analysis
  • [MeSH-minor] Adolescent. Adult. Child. Female. Glypicans / analysis. Humans. Immunohistochemistry. Infant, Newborn. Male. Octamer Transcription Factor-3 / analysis. Predictive Value of Tests. Sensitivity and Specificity. Young Adult. alpha-Fetoproteins / analysis

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820689.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AFP protein, human; 0 / Biomarkers, Tumor; 0 / GPC3 protein, human; 0 / Glypicans; 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human; 0 / SALL4 protein, human; 0 / Transcription Factors; 0 / alpha-Fetoproteins
  •  go-up   go-down


67. Park KK, Liu K, Hu Y, Smith PD, Wang C, Cai B, Xu B, Connolly L, Kramvis I, Sahin M, He Z: Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway. Science; 2008 Nov 7;322(5903):963-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway.
  • The failure of axons to regenerate is a major obstacle for functional recovery after central nervous system (CNS) injury.
  • Deletion of PTEN (phosphatase and tensin homolog), a negative regulator of the mammalian target of rapamycin (mTOR) pathway, in adult retinal ganglion cells (RGCs) promotes robust axon regeneration after optic nerve injury.
  • In wild-type adult mice, the mTOR activity was suppressed and new protein synthesis was impaired in axotomized RGCs, which may contribute to the regeneration failure.
  • Thus, our results suggest the manipulation of intrinsic growth control pathways as a therapeutic approach to promote axon regeneration after CNS injury.


68. Wang ZH, Shi HY, Wang ZB: [Metastatic alveolar soft tissue sarcoma of the central nervous system: a clinicopathological analysis of four cases]. Ai Zheng; 2009 Nov;28(11):1214-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastatic alveolar soft tissue sarcoma of the central nervous system: a clinicopathological analysis of four cases].
  • BACKGROUND AND OBJECTIVE: Metastatic alveolar soft tissue sarcoma (ASTS) of the central nervous system is rare and is easy to be misdiagnosed as other primary tumors of central nervous system.
  • This study was to analyze the clinical and pathological features of four patients with ASTS of the central nervous system and to clarify their differential diagnosis as well as prognosis.
  • The tumor cells had clear or eosinophilic cytoplasm and prominent nucleoli, arranged in alveolar structures, which were surrounded by delicate blood sinuses.
  • CONCLUSION: ASTS of the central nervous system was mostly metastatic and should be differentiated from other CNS tumors such as meningioma, melonocytic tumor, rhabdomyosarcoma and paraganglioma.
  • Metastatic ASTS of the central nervous system had poor prognosis and the five-year survival rate was low.
  • [MeSH-major] Cranial Fossa, Posterior. Sarcoma, Alveolar Soft Part / pathology. Sarcoma, Alveolar Soft Part / secondary. Skull Base Neoplasms / pathology. Skull Base Neoplasms / secondary
  • [MeSH-minor] Actins / metabolism. Adult. Desmin / metabolism. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Neoplasm Recurrence, Local. Paraganglioma / diagnosis. Prognosis. Rhabdomyosarcoma / diagnosis. S100 Proteins / metabolism. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19895745.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Actins; 0 / Desmin; 0 / S100 Proteins
  •  go-up   go-down


69. Umredkar A, Bal A, Vashista RK: Atypical teratoid/rhabdoid tumour of the central nervous system in adult: case report. Br J Neurosurg; 2010 Dec;24(6):699-704
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical teratoid/rhabdoid tumour of the central nervous system in adult: case report.
  • Atypical teratoid/rhabdoid tumours (AT/RT) are aggressive neoplasms of the central nervous system occurring mainly in the paediatric population.
  • The neoplasm was localised in the left frontal region and was totally excised.
  • This unusual presentation underlines the necessity of considering this devastating neoplasm in the differential diagnosis of malignant brain tumours of adults.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Rhabdoid Tumor / pathology. Teratoma / pathology
  • [MeSH-minor] Adult. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21070155.001).
  • [ISSN] 1360-046X
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


70. Kiewe P, Loddenkemper C, Anagnostopoulos I, Reinwald M, Thiel E, Korfel A: High-dose methotrexate is beneficial in parenchymal brain masses of uncertain origin suspicious for primary CNS lymphoma. Neuro Oncol; 2007 Apr;9(2):96-102
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose methotrexate is beneficial in parenchymal brain masses of uncertain origin suspicious for primary CNS lymphoma.
  • In patients with parenchymal brain masses of uncertain origin responsive to corticosteroids, primary CNS lymphoma (PCNSL) should be considered.
  • PCNSL is a rare but aggressive brain tumor that is highly sensitive to high-dose methotrexate (HDMTX)-based chemotherapy.
  • [MeSH-major] Brain Neoplasms / drug therapy. Central Nervous System Neoplasms / drug therapy. Lymphoma / drug therapy. Methotrexate / therapeutic use
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / therapeutic use. Biopsy. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Recurrence. Stereotaxic Techniques

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 1999 Jul;43(3):231-6 [10563428.001]
  • [Cites] Clin Imaging. 2004 Jul-Aug;28(4):261-70 [15246475.001]
  • [Cites] Eur J Endocrinol. 2000 Apr;142(4):365-72 [10754478.001]
  • [Cites] Mol Pathol. 2000 Aug;53(4):194-200 [11040942.001]
  • [Cites] J R Soc Med. 2000 Nov;93(11):586-8 [11198690.001]
  • [Cites] Neurology. 2001 May 22;56(10):1313-8 [11376180.001]
  • [Cites] J Neurol. 2001 Jun;248(6):451-68 [11499635.001]
  • [Cites] Neurology. 2001 Aug 14;57(3):393-6 [11515505.001]
  • [Cites] Neurology. 2002 Feb 12;58(3):390-6 [11839837.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):354-62 [12186464.001]
  • [Cites] Neurology. 2002 Sep 10;59(5):762-4 [12221174.001]
  • [Cites] Neurology. 1988 Jul;38(7):1153-5 [3386836.001]
  • [Cites] Cancer. 1988 Dec 1;62(11):2461-5 [3179963.001]
  • [Cites] AJNR Am J Neuroradiol. 1989 Jul-Aug;10(4):725-9 [2505501.001]
  • [Cites] Br J Neurosurg. 1990;4(5):407-15 [2261103.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(1):9-17 [1572835.001]
  • [Cites] AJNR Am J Neuroradiol. 1992 Jul-Aug;13(4):1207-13 [1636538.001]
  • [Cites] J Nucl Med. 1993 Apr;34(4):567-75 [8455072.001]
  • [Cites] J Neurosurg. 1994 Aug;81(2):188-95 [8027800.001]
  • [Cites] Oncology (Williston Park). 1995 Jan;9(1):63-71; discussion 71, 75-6, 78 [7718442.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1996 Jan;60(1):102-5 [8558135.001]
  • [Cites] Ophthalmology. 1996 Mar;103(3):521-8 [8600431.001]
  • [Cites] Clin Imaging. 1996 Jul-Sep;20(3):171-7 [8877168.001]
  • [Cites] Neuroradiology. 1996 Aug;38(6):560-5 [8880719.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):859-63 [9508166.001]
  • [Cites] Cancer. 1998 May 1;82(9):1749-55 [9576298.001]
  • [Cites] J Neurol Sci. 2004 Dec 15;227(1):85-9 [15546596.001]
  • [Cites] J Neurooncol. 2005 Jan;71(2):173-80 [15690135.001]
  • [Cites] Br J Haematol. 2005 Mar;128(5):616-24 [15725082.001]
  • [Cites] Neurol Sci. 2004 Nov;25 Suppl 4:S361-3 [15727234.001]
  • [Cites] J Neurooncol. 2005 Apr;72(2):169-77 [15925998.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]
  • [Cites] QJM. 2005 Sep;98(9):643-54 [16040668.001]
  • [Cites] Neurology. 2005 Oct 11;65(7):1057-65 [16217059.001]
  • [Cites] Arch Neurol. 2005 Nov;62(11):1673-80 [16286539.001]
  • [Cites] Clin Neurol Neurosurg. 2007 Jan;109(1):92-101 [16644103.001]
  • [Cites] Neurosci Lett. 2003 Feb 27;338(2):119-22 [12566167.001]
  • [Cites] Neurosci Lett. 2003 May 22;342(3):163-6 [12757890.001]
  • [Cites] Br J Radiol. 2004 Feb;77(914):153-6 [15010391.001]
  • [Cites] Arq Neuropsiquiatr. 1999 Dec;57(4):921-6 [10683680.001]
  • (PMID = 17301290.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC1871672
  •  go-up   go-down


71. Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M, Vandenberg SR, Ginzinger DG, James CD, Costello JF, Bergers G, Weiss WA, Alvarez-Buylla A, Hodgson JG: miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med; 2008 Jun 24;6:14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells.
  • BACKGROUND: Glioblastoma multiforme (GBM) is an invariably fatal central nervous system tumor despite treatment with surgery, radiation, and chemotherapy.
  • In this study, we investigated the role of microRNAs in regulating the differentiation and proliferation of neural stem cells and glioblastoma-multiforme tumor cells.
  • METHODS: We used quantitative RT-PCR to assess microRNA expression in high-grade astrocytomas and adult mouse neural stem cells.
  • Transfection of microRNA-124 or microRNA-137 induced morphological changes and marker expressions consistent with neuronal differentiation in mouse neural stem cells, mouse oligodendroglioma-derived stem cells derived from S100 beta-v-erbB tumors and cluster of differentiation 133+ human glioblastoma multiforme-derived stem cells (SF6969).
  • CONCLUSION: microRNA-124 and microRNA-137 induce differentiation of adult mouse neural stem cells, mouse oligodendroglioma-derived stem cells and human glioblastoma multiforme-derived stem cells and induce glioblastoma multiforme cell cycle arrest.
  • These results suggest that targeted delivery of microRNA-124 and/or microRNA-137 to glioblastoma multiforme tumor cells may be therapeutically efficacious for the treatment of this disease.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gene Ther. 2006 Apr;13(7):646-51 [16341056.001]
  • [Cites] RNA. 2006 Feb;12(2):187-91 [16373485.001]
  • [Cites] Cancer Cell. 2006 May;9(5):391-403 [16697959.001]
  • [Cites] Technol Cancer Res Treat. 2006 Jun;5(3):261-9 [16700622.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):435-43 [16766263.001]
  • [Cites] Neuro Oncol. 2006 Jul;8(3):205-14 [16723630.001]
  • [Cites] Nat Genet. 2006 Sep;38(9):1060-5 [16878133.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Sep;91(9):3584-91 [16822819.001]
  • [Cites] Oncogene. 2006 Oct 9;25(46):6156-62 [17028594.001]
  • [Cites] Mol Pharm. 2006 Nov-Dec;3(6):726-36 [17140260.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):761-5 [17151667.001]
  • [Cites] Neuro Oncol. 2007 Jan;9(1):20-8 [17018695.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7261-70 [17189397.001]
  • [Cites] Neurosurg Clin N Am. 2007 Jan;18(1):39-58, viii [17244553.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1424-9 [17308079.001]
  • [Cites] Genes Dev. 2007 Mar 1;21(5):531-6 [17344415.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2456-68 [17363563.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):1167-74 [17363510.001]
  • [Cites] Exp Hematol. 2007 Apr;35(4):551-64 [17379065.001]
  • [Cites] Genes Dev. 2007 Apr 1;21(7):744-9 [17403776.001]
  • [Cites] Nat Genet. 2007 May;39(5):673-7 [17401365.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1401-14 [17604727.001]
  • [Cites] Mol Cell. 2007 Aug 3;27(3):435-48 [17679093.001]
  • [Cites] Cell Cycle. 2007 Aug 15;6(16):2005-9 [17721077.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):8994-9000 [17908999.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):112-20 [18287341.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1589-95 [12670909.001]
  • [Cites] RNA. 2003 Oct;9(10):1274-81 [13130141.001]
  • [Cites] Nat Genet. 2003 Nov;35(3):217-8 [14528306.001]
  • [Cites] Nat Genet. 2003 Nov;35(3):215-7 [14528307.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jan;39(1):29-36 [14603439.001]
  • [Cites] Genome Biol. 2004;5(3):R13 [15003116.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3753-6 [15172979.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] J Biochem. 2005 Mar;137(3):381-6 [15809340.001]
  • [Cites] Eur J Neurosci. 2005 Mar;21(6):1469-77 [15845075.001]
  • [Cites] Exp Cell Res. 2005 Jun 10;306(2):323-9 [15925587.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):974-8 [15944714.001]
  • [Cites] Stem Cells. 2006 Apr;24(4):857-64 [16357340.001]
  • [Cites] Cell Cycle. 2006 Feb;5(3):266-70 [16410727.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9353-8 [15961540.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6029-33 [16024602.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 9;334(4):1351-8 [16039986.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12135-40 [16099834.001]
  • [Cites] Cell. 2005 Dec 29;123(7):1267-77 [16377567.001]
  • [CommentIn] BMC Med. 2008;6:15 [18577221.001]
  • (PMID = 18577219.001).
  • [ISSN] 1741-7015
  • [Journal-full-title] BMC medicine
  • [ISO-abbreviation] BMC Med
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS028478; United States / NINDS NIH HHS / NS / NS28478; United States / NCI NIH HHS / CA / K01 CA101777; United States / NCI NIH HHS / CA / P50 CA097257; United States / NCI NIH HHS / CA / CA097257; United States / NCI NIH HHS / CA / CA101777; United States / NINDS NIH HHS / NS / R37 NS028478
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MIRN124 microRNA, human; 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2443372
  •  go-up   go-down


72. Martin DS, Walsh M, Miller AM, Skerrett HE, Byrne P, Mandel A, Bolton AE, Lynch MA: A novel phospholipid-based drug formulation, VP025, modulates age- and LPS-induced microglial activity in the rat. Neuroimmunomodulation; 2009;16(6):400-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A common change that occurs with age in the central nervous system is an increase in microglial-associated inflammation.
  • [MeSH-minor] Adult. Animals. Hippocampus / drug effects. Hippocampus / metabolism. Hippocampus / physiopathology. Humans. Immunomodulation / drug effects. Immunomodulation / physiology. Interferon-gamma / metabolism. Interferon-gamma / secretion. Interleukin-1beta / metabolism. Interleukin-1beta / secretion. Long-Term Potentiation / drug effects. Long-Term Potentiation / physiology. Macrophages / drug effects. Macrophages / metabolism. Male. Memory Disorders / drug therapy. Memory Disorders / metabolism. Memory Disorders / physiopathology. Nanoparticles / chemistry. Perforant Pathway / drug effects. Perforant Pathway / metabolism. Perforant Pathway / physiopathology. Phagocytosis / drug effects. Phagocytosis / physiology. Rats. Rats, Wistar. Tumor Cells, Cultured. Tumor Necrosis Factor-alpha / metabolism. Tumor Necrosis Factor-alpha / secretion

  • MedlinePlus Health Information. consumer health - Encephalitis.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19609089.001).
  • [ISSN] 1423-0216
  • [Journal-full-title] Neuroimmunomodulation
  • [ISO-abbreviation] Neuroimmunomodulation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Interleukin-1beta; 0 / Phosphatidylglycerols; 0 / Phospholipids; 0 / Tumor Necrosis Factor-alpha; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


73. Küker W, Nägele T, Thiel E, Weller M, Herrlinger U: Primary central nervous system lymphomas (PCNSL): MRI response criteria revised. Neurology; 2005 Oct 11;65(7):1129-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphomas (PCNSL): MRI response criteria revised.
  • The authors investigated the applicability of Macdonald response criteria to patients with primary CNS lymphoma (PCNSL).
  • Four of 68 patients with persisting contrast-enhancing lesions after primary therapy did not receive further therapy, and none showed tumor progression after up to 54 months.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Central Nervous System Neoplasms / diagnosis. Lymphoma / diagnosis. Magnetic Resonance Imaging / methods. Magnetic Resonance Imaging / standards. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Aged. Contrast Media. Disease Progression. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neurology. 2006 Apr 25;66(8):1287; author reply 1287 [16636266.001]
  • (PMID = 16217075.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Contrast Media
  •  go-up   go-down


74. Raizer JJ, Koutcher JA, Abrey LE, Panageas KS, DeAngelis LM, Lis E, Xu S, Zakian KL: Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma. J Neurooncol; 2005 Jan;71(2):173-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma.
  • Primary central nervous system lymphoma (PCNSL) is a highly aggressive tumor responsive to high-dose methotrexate based regimens.
  • MRSI correlated with tumor response or progression on MRI; in three patients MRSI suggested disease progression prior to changes on MRI.
  • CONCLUSION: MRSI and MRI correlate with tumor response or progression and may allow early detection of disease recurrence.
  • [MeSH-major] Aspartic Acid / analogs & derivatives. Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / immunology. Immunocompetence. Lymphoma / diagnosis. Lymphoma / immunology. Magnetic Resonance Spectroscopy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / therapeutic use. Choline / metabolism. Creatine / metabolism. Disease Progression. Dose-Response Relationship, Drug. Female. Humans. Lactic Acid / metabolism. Lipid Metabolism. Magnetic Resonance Imaging. Male. Methotrexate / administration & dosage. Methotrexate / therapeutic use. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Protons. Survival Analysis

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LACTIC ACID .
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. CREATINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2000 Jan;21(1):84-93 [10669230.001]
  • [Cites] Radiology. 1993 Mar;186(3):745-52 [8430183.001]
  • [Cites] Neurosurgery. 2000 Feb;46(2):319-26; discussion 326-8 [10690720.001]
  • [Cites] Curr Opin Oncol. 2002 May;14(3):292-8 [11981274.001]
  • [Cites] Anticancer Res. 1996 May-Jun;16(3B):1533-8 [8694522.001]
  • [Cites] Invest Radiol. 1997 May;32(5):288-96 [9140749.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):215-26 [11263501.001]
  • [Cites] Radiology. 1995 Jan;194(1):271-6 [7997566.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1271-6 [11955739.001]
  • [Cites] Anticancer Res. 1996 May-Jun;16(3B):1485-9 [8694517.001]
  • [Cites] Can J Neurol Sci. 1998 Feb;25(1):13-22 [9532276.001]
  • [Cites] Magn Reson Med. 2003 Feb;49(2):223-32 [12541241.001]
  • [Cites] NMR Biomed. 2003 Feb;16(1):12-8 [12577293.001]
  • [Cites] Neurosci Lett. 2003 May 22;342(3):163-6 [12757890.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Jan;20(1):117-23 [9974066.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):915-28 [11429219.001]
  • [Cites] J Neurooncol. 1990 Oct;9(2):177-81 [2262803.001]
  • [Cites] Neuroradiology. 2001 Feb;43(2):169-77 [11326567.001]
  • [Cites] J Neurosurg. 1996 Mar;84(3):449-58 [8609557.001]
  • [Cites] Anticancer Res. 1996 May-Jun;16(3B):1565-7 [8694527.001]
  • [Cites] Neurology. 2002 Nov 26;59(10):1557-62 [12451197.001]
  • [Cites] Curr Opin Oncol. 2000 May;12(3):199-204 [10841191.001]
  • [Cites] Science. 1982 Jun 18;216(4552):1325-7 [7079765.001]
  • [Cites] Radiology. 1995 Dec;197(3):649-54 [7480733.001]
  • [Cites] J Neurosurg. 1997 Oct;87(4):525-34 [9322843.001]
  • [Cites] NMR Biomed. 1999 Nov;12(7):413-39 [10654290.001]
  • [Cites] Magn Reson Med. 1990 Oct;16(1):1-8 [2255232.001]
  • [Cites] NMR Biomed. 2002 Oct;15(6):385-92 [12357552.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1044-9 [12637469.001]
  • [Cites] Neurosurgery. 2000 Feb;46(2):306-18 [10690719.001]
  • [Cites] Radiology. 1995 Nov;197(2):525-31 [7480706.001]
  • [Cites] Neurosurgery. 2002 Oct;51(4):912-9; discussion 919-20 [12234397.001]
  • [Cites] Radiology. 1992 Dec;185(3):675-86 [1438744.001]
  • [Cites] Nat Med. 1996 Mar;2(3):323-5 [8612232.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Apr;22(4):604-12 [11290466.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3144-50 [10963643.001]
  • [Cites] J Neurooncol. 1993 Jul;17(1):27-35 [8120569.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1998 Apr;64(4):516-23 [9576546.001]
  • [Cites] Radiology. 1987 Oct;165(1):215-9 [3628774.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Apr;21(4):659-65 [10782774.001]
  • [Cites] Neuroradiology. 2000 Oct;42(10):738-41 [11110076.001]
  • (PMID = 15690135.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Protons; 30KYC7MIAI / Aspartic Acid; 33X04XA5AT / Lactic Acid; 997-55-7 / N-acetylaspartate; MU72812GK0 / Creatine; N91BDP6H0X / Choline; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


75. Rivera AL, Pelloski CE: Diagnostic and prognostic molecular markers in common adult gliomas. Expert Rev Mol Diagn; 2010 Jul;10(5):637-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and prognostic molecular markers in common adult gliomas.
  • The majority of primary CNS tumors in adults are comprised of gliomas (astrocytomas, oligodendrogliomas and ependymomas).
  • The diagnosis has historically been based on the histologic appearance of these tumors.
  • In this article, we summarize the findings of important, published biomarker studies in adult gliomas and provide an overview of the practical uses of these markers in the clinical setting, as well as the current understanding of molecular gliomagenesis.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / therapy. Glioma / diagnosis. Glioma / therapy
  • [MeSH-minor] Adult. Clinical Trials as Topic. Gene Expression Profiling. Humans. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20629512.001).
  • [ISSN] 1744-8352
  • [Journal-full-title] Expert review of molecular diagnostics
  • [ISO-abbreviation] Expert Rev. Mol. Diagn.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


76. Ambrosini-Spaltro A, Eusebi V: Meningeal hemangiopericytomas and hemangiopericytoma/solitary fibrous tumors of extracranial soft tissues: a comparison. Virchows Arch; 2010 Apr;456(4):343-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningeal hemangiopericytomas and hemangiopericytoma/solitary fibrous tumors of extracranial soft tissues: a comparison.
  • The current World Health Organization (WHO) classification of central nervous system tumors lists meningeal hemangiopericytomas (HPC) and meningeal solitary fibrous tumors (SFT) as separate entities.
  • Nevertheless, intracranial tumors were more cellular than HPC-SFT of soft tissues and had fewer collagen bands.
  • Both meningeal and soft tissue tumors appear to represent different features of the same entity.
  • A more aggressive phenotype of the tumor together with incomplete surgical resection of intracranial lesions might explain the noticeable clinical difference between HPC of the meninges and HPC-SFT of soft tissues.
  • [MeSH-major] Hemangiopericytoma / pathology. Meningeal Neoplasms / pathology. Soft Tissue Neoplasms / pathology. Solitary Fibrous Tumors / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD34 / metabolism. Collagen / metabolism. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / metabolism. Recurrence. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1986 Aug;65(2):168-71 [3723173.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(12):1399-408 [9030346.001]
  • [Cites] Mod Pathol. 1999 Nov;12(11):1034-42 [10574600.001]
  • [Cites] Am J Surg Pathol. 1989 Aug;13(8):640-58 [2665534.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1746-51 [12365023.001]
  • [Cites] Hum Pathol. 1999 Dec;30(12):1464-73 [10667425.001]
  • [Cites] Virchows Arch. 2004 May;444(5):459-64 [15014990.001]
  • [Cites] Am J Surg Pathol. 1994 Mar;18(3):281-7 [8116796.001]
  • [Cites] Hum Pathol. 1991 Jan;22(1):84-91 [1985083.001]
  • [Cites] Cancer. 1954 May;7(3):602-6 [13160944.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12 ):1501-11 [9850176.001]
  • [Cites] Histopathology. 1996 May;28(5):463-6 [8735723.001]
  • [Cites] Ann Surg. 1942 Jul;116(1):26-33 [17858068.001]
  • [Cites] J Neurosurg. 2000 Sep;93(3):490-3 [10969951.001]
  • [Cites] Am J Surg Pathol. 2009 Sep;33(9):1314-21 [19718788.001]
  • [Cites] Am J Clin Pathol. 1996 Aug;106(2):217-24 [8712177.001]
  • [Cites] Mod Pathol. 1997 May;10(5):443-50 [9160308.001]
  • [Cites] Neurosurgery. 1989 Oct;25(4):514-22 [2797389.001]
  • [Cites] Clin Neurol Neurosurg. 2009 Jan;111(1):34-8 [18922629.001]
  • [Cites] J Neurooncol. 2001 Aug;54(1):57-69 [11763424.001]
  • [Cites] Clin Neuropathol. 2005 Nov-Dec;24(6):252-6 [16320818.001]
  • [Cites] J Neurosurg. 2004 Dec;101(6):1045-8 [15597767.001]
  • [Cites] Hum Pathol. 1990 Apr;21(4):414-23 [2318483.001]
  • [Cites] Am J Surg Pathol. 1997 Nov;21(11):1354-60 [9351573.001]
  • [Cites] Arch Pathol Lab Med. 2003 Apr;127(4):432-9 [12683870.001]
  • (PMID = 20165866.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Proto-Oncogene Proteins c-bcl-2; 9007-34-5 / Collagen
  •  go-up   go-down


77. Klosky JL, Randolph ME, Navid F, Gamble HL, Spunt SL, Metzger ML, Daw N, Morris EB, Hudson MM: Sperm cryopreservation practices among adolescent cancer patients at risk for infertility. Pediatr Hematol Oncol; 2009 Jun;26(4):252-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Utilization of sperm banking was significantly associated with a diagnosis of central nervous system (CNS) malignancy or non-CNS solid tumor diagnosis, higher socioeconomic status, and not being a member of an Evangelical religious group.

  • Genetic Alliance. consumer health - infertility.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Male Infertility.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Endocrinol. 2000 Nov 27;169(1-2):117-22 [11155943.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jan;50(1):85-9 [17514741.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1880-9 [11919248.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1890-7 [11919249.001]
  • [Cites] Arch Dis Child. 2004 Aug;89(8):736-7 [15269072.001]
  • [Cites] Hum Reprod Update. 2004 Nov-Dec;10(6):525-32 [15319377.001]
  • [Cites] Cancer. 1992 Dec 1;70(11):2703-12 [1423201.001]
  • [Cites] Cancer. 1999 Aug 15;86(4):697-709 [10440699.001]
  • [Cites] Psychooncology. 2004 Oct;13(10):689-99 [15386645.001]
  • [Cites] Psychooncology. 2004 Dec;13(12):867-81 [15386796.001]
  • [Cites] J Natl Cancer Inst Monogr. 2005;(34):101-3 [15784836.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2917-31 [16651642.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Jun;28(6):350-4 [16794502.001]
  • [Cites] Hum Reprod. 2007 May;22(5):1384-95 [17259225.001]
  • [Cites] Cancer. 2007 Sep 1;110(5):1125-9 [17647219.001]
  • [Cites] Cancer. 2001 Feb 1;91(3):613-21 [11169946.001]
  • (PMID = 19437327.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] ENG
  • [Grant] None / None / / P30 CA021765-31; United States / NCI NIH HHS / CA / CA23099; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / P01 CA023099; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / P30 CA021765-31
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS162120; NLM/ PMC2801903
  •  go-up   go-down


78. Kim KE, Kim KU, Kim DC, Park JI, Han JY: Cytogenetic characterizations of central nervous system tumors: the first comprehensive report from a single institution in Korea. J Korean Med Sci; 2009 Jun;24(3):453-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic characterizations of central nervous system tumors: the first comprehensive report from a single institution in Korea.
  • The World Health Organization (WHO) classification of central nervous system (CNS) tumors incorporates morphology, cytogenetics, molecular genetics, and immunologic markers.
  • Despite the relatively large number of CNS tumors with clonal chromosome abnormalities, only few studies have investigated cytogenetic abnormalities for CNS tumors in Korea.
  • Thus, we investigated 119 CNS tumors by conventional G-banded karyotypes to characterize patterns of chromosomal abnormalities involving various CNS tumors, and 92.4% of them were cultured and karyotyped successfully.
  • Totally, 51.8% of karyotypable CNS tumors showed abnormal cytogenetic results, including neuroepithelial tumors (75.0%), meningeal tumors (71.1%), pituitary adenomas (4.2%), schwannomas (44.4%), and metastatic tumors (100.0%).
  • Abnormal karyotypes were more complex at high-grade tumors, suggesting that the karyotype reflects the biologic nature of the tumor.
  • More detailed cytogenetic and molecular characterizations of CNS tumors contribute to better diagnostic criteria and deeper insights of tumorigenesis, eventually resulting in development of novel therapeutic strategies.
  • [MeSH-major] Asian Continental Ancestry Group / genetics. Central Nervous System Neoplasms / genetics. Chromosome Aberrations
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Glioblastoma / genetics. Humans. Karyotyping. Korea. Male. Meningeal Neoplasms / genetics. Middle Aged. Neurilemmoma / genetics. Pituitary Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2000 Jun;48(2):95-101 [11083072.001]
  • [Cites] Expert Rev Neurother. 2004 Jul;4(4):649-63 [15853584.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):199-201 [11161377.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Mar;33(3):279-84 [11807985.001]
  • [Cites] J Neurosurg. 2002 Mar;96(3):559-64 [11892633.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jun;135(2):147-59 [12127399.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Apr 1;142(1):1-7 [12660025.001]
  • [Cites] Adv Anat Pathol. 2003 Jul;10(4):212-7 [12826827.001]
  • [Cites] Childs Nerv Syst. 2003 Jun;19(5-6):270-85 [12761644.001]
  • [Cites] J Med Genet. 2003 Nov;40(11):802-6 [14627667.001]
  • [Cites] Neurosurg Rev. 2004 Jan;27(1):58-64 [12845540.001]
  • [Cites] Cancer Genet Cytogenet. 2004 May;151(1):36-51 [15120909.001]
  • [Cites] Hum Mol Genet. 1994 Aug;3(8):1393-9 [7987321.001]
  • [Cites] Oncogene. 1995 Apr 20;10(8):1521-8 [7731706.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Oct;14(2):85-96 [8527398.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Sep;90(2):109-17 [8830718.001]
  • [Cites] Cancer Res. 1996 Nov 15;56(22):5141-5 [8912848.001]
  • [Cites] Cancer Genet Cytogenet. 1997 May;95(1):1-8 [9140447.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2765-80 [9205089.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Aug;97(1):39-53 [9242217.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):598-603 [9892679.001]
  • [Cites] J Pathol. 1999 Aug;188(4):395-9 [10440750.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):137-60 [15674475.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2653-61 [15805262.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(10):1099-104; discussion 1104-5 [11129530.001]
  • (PMID = 19543509.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2698192
  • [Keywords] NOTNLM ; Central Nervous System Neoplasms / Chromosome Abnormality / Karyotype / Solid Tumor / WHO Classification
  •  go-up   go-down


79. Vudattu NK, Kuhlmann-Berenzon S, Khademi M, Seyfert V, Olsson T, Maeurer MJ: Increased numbers of IL-7 receptor molecules on CD4+CD25-CD107a+ T-cells in patients with autoimmune diseases affecting the central nervous system. PLoS One; 2009;4(8):e6534
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased numbers of IL-7 receptor molecules on CD4+CD25-CD107a+ T-cells in patients with autoimmune diseases affecting the central nervous system.
  • BACKGROUND: High content immune profiling in peripheral blood may reflect immune aberrations associated with inflammation in multiple sclerosis (MS) and other autoimmune diseases affecting the central nervous system.
  • We identified 19 variables for immune cell subsets (percentages) which allowed to segregate healthy individuals and individuals with CNS disorders.
  • [MeSH-major] Antigens, CD4 / analysis. Autoimmune Diseases / metabolism. Central Nervous System Diseases / metabolism. Interleukin-2 Receptor alpha Subunit / analysis. Lysosomal-Associated Membrane Protein 1 / analysis. Receptors, Interleukin-7 / metabolism. T-Lymphocytes / metabolism
  • [MeSH-minor] Adult. Cluster Analysis. Female. Humans. Immunophenotyping. Male. Middle Aged

  • Genetic Alliance. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuroimmunol. 1999 Dec;100(1-2):115-23 [10695722.001]
  • [Cites] PLoS One. 2008;3(11):e3790 [19023426.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1491-7 [11222398.001]
  • [Cites] J Exp Med. 2001 Jun 4;193(11):1303-10 [11390437.001]
  • [Cites] J Immunol. 2003 Oct 1;171(7):3348-52 [14500627.001]
  • [Cites] J Exp Med. 2004 Apr 5;199(7):971-9 [15067033.001]
  • [Cites] Science. 2004 Apr 23;304(5670):590-3 [15105501.001]
  • [Cites] J Exp Med. 2004 Aug 2;200(3):277-85 [15280421.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14599-606 [15306684.001]
  • [Cites] N Engl J Med. 1980 Jul 17;303(3):125-9 [6446039.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6452-6 [1830662.001]
  • [Cites] Annu Rev Immunol. 2005;23:683-747 [15771584.001]
  • [Cites] Neurol Res. 2006 Apr;28(3):256-61 [16687050.001]
  • [Cites] J Exp Med. 2006 Jul 10;203(7):1693-700 [16818676.001]
  • [Cites] J Exp Med. 2006 Jul 10;203(7):1701-11 [16818678.001]
  • [Cites] Brain. 2006 Aug;129(Pt 8):1993-2007 [16870883.001]
  • [Cites] J Exp Med. 2006 Dec 25;203(13):2865-77 [17158960.001]
  • [Cites] Int Rev Neurobiol. 2007;79:73-97 [17531838.001]
  • [Cites] Int J Cancer. 2007 Oct 1;121(7):1512-9 [17546596.001]
  • [Cites] Nat Genet. 2007 Sep;39(9):1083-91 [17660817.001]
  • [Cites] J Neuroimmunol. 2007 Dec;192(1-2):171-3 [17913246.001]
  • [Cites] Int Immunol. 2008 Mar;20(3):421-31 [18270368.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):2999-3004 [18287017.001]
  • [Cites] Ann Rheum Dis. 2008 Jul;67(7):1037-40 [18199598.001]
  • [Cites] Arthritis Rheum. 2008 Jul;58(7):2120-30 [18576316.001]
  • [Cites] Brain. 2008 Jul;131(Pt 7):1701-11 [18567923.001]
  • [Cites] J Clin Invest. 2008 Oct;118(10):3411-9 [18769633.001]
  • [Cites] J Immunother. 2008 Nov-Dec;31(9):840-8 [18833003.001]
  • [Cites] N Engl J Med. 2000 Sep 28;343(13):938-52 [11006371.001]
  • (PMID = 19657390.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Interleukin-2 Receptor alpha Subunit; 0 / Lysosomal-Associated Membrane Protein 1; 0 / Receptors, Interleukin-7
  • [Other-IDs] NLM/ PMC2717329
  •  go-up   go-down


80. Hurst LA, Bunning RA, Couraud PO, Romero IA, Weksler BB, Sharrack B, Woodroofe MN: Expression of ADAM-17, TIMP-3 and fractalkine in the human adult brain endothelial cell line, hCMEC/D3, following pro-inflammatory cytokine treatment. J Neuroimmunol; 2009 May 29;210(1-2):108-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of ADAM-17, TIMP-3 and fractalkine in the human adult brain endothelial cell line, hCMEC/D3, following pro-inflammatory cytokine treatment.
  • ADAM-17 expression is localised to endothelial cells in the human central nervous system (CNS) and is increased in multiple sclerosis (MS) white matter, suggesting a role in MS pathogenesis.
  • Fractalkine shedding may regulate immune cell trafficking into the CNS, however, this does not appear to be directly controlled by ADAM-17 activity.
  • [MeSH-minor] Cell Line. Chemotaxis, Leukocyte / immunology. Encephalitis / immunology. Encephalitis / metabolism. Encephalitis / physiopathology. Gene Expression / drug effects. Gene Expression / physiology. Humans. RNA, Messenger / analysis. RNA, Messenger / drug effects. RNA, Messenger / metabolism. Tissue Inhibitor of Metalloproteinase-3 / genetics. Tissue Inhibitor of Metalloproteinase-3 / metabolism. Tumor Necrosis Factor-alpha / metabolism. Tumor Necrosis Factor-alpha / pharmacology. Up-Regulation / drug effects. Up-Regulation / immunology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19324423.001).
  • [ISSN] 1872-8421
  • [Journal-full-title] Journal of neuroimmunology
  • [ISO-abbreviation] J. Neuroimmunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CX3CL1 protein, human; 0 / Chemokine CX3CL1; 0 / Cytokines; 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinase-3; 0 / Tumor Necrosis Factor-alpha; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / tumor necrosis factor-alpha convertase
  •  go-up   go-down


81. Koh ES, Nichol A, Millar BA, Ménard C, Pond G, Laperriere NJ: Role of fractionated external beam radiotherapy in hemangioblastoma of the central nervous system. Int J Radiat Oncol Biol Phys; 2007 Dec 1;69(5):1521-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of fractionated external beam radiotherapy in hemangioblastoma of the central nervous system.
  • PURPOSE: To assess the clinical outcomes and toxicity in patients receiving fractionated external beam radiotherapy (EBRT) for hemangioblastoma of the central nervous system, treated at two Canadian radiation oncology institutions.
  • METHODS AND MATERIALS: Between January 1980 and December 2004, the data of all patients receiving EBRT for central nervous system hemangioblastoma were retrospectively reviewed.
  • The patient, tumor, and treatment characteristics were collected and overall survival, disease-free survival, and EBRT-related toxicities assessed.
  • [MeSH-major] Cerebellar Neoplasms / radiotherapy. Hemangioblastoma / radiotherapy. Spinal Cord Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. British Columbia. Disease-Free Survival. Dose Fractionation. Female. Humans. Male. Middle Aged. Ontario. Radiation Injuries / complications. Retrospective Studies. von Hippel-Lindau Disease / complications

  • Genetic Alliance. consumer health - Hemangioblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17869023.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


82. Rood BR, MacDonald TJ: Pediatric high-grade glioma: molecular genetic clues for innovative therapeutic approaches. J Neurooncol; 2005 Dec;75(3):267-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High grade glioma remains the most intractable childhood tumor of the central nervous system.
  • The molecular genetics of childhood high grade glioma remain largely unknown in comparison to that of their adult counterparts.
  • In this review, we discuss the current understanding of the molecular genetics of childhood high grade glioma and compare/contrast it to that of the adult tumors bearing the same classification for the purpose of beginning to identify the most promising therapeutic targets.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / genetics. Genes, Neoplasm. Glioma / drug therapy. Glioma / genetics. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Age Factors. Antineoplastic Agents / pharmacology. Child. DNA Damage. DNA Repair. Humans. Microsatellite Repeats. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2001 May;31(1):15-22 [11284031.001]
  • [Cites] Brain Pathol. 1998 Oct;8(4):655-67 [9804374.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1786-92 [10430083.001]
  • [Cites] Clin Neuropathol. 2003 Jul-Aug;22(4):180-6 [12908754.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6962-70 [14583498.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12 ):4085-90 [10632344.001]
  • [Cites] Cancer. 2000 Oct 1;89(7):1569-76 [11013373.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):164-71 [8548759.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1122-8 [11221842.001]
  • [Cites] J Neurooncol. 2002 Sep;59(2):117-22 [12241104.001]
  • [Cites] J Neurosurg. 1996 Jun;84(6):1020-3 [8847566.001]
  • [Cites] J Korean Med Sci. 2000 Oct;15(5):555-9 [11068994.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4187-90 [9331072.001]
  • [Cites] Br J Neurosurg. 1993;7(2):197-9 [8388222.001]
  • [Cites] Curr Neurol Neurosci Rep. 2004 May;4(3):228-33 [15102349.001]
  • [Cites] Pediatr Neurosurg. 1996 Jul;25(1):45-53 [9055335.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1865-70 [12702575.001]
  • [Cites] J Neuropathol Exp Neurol. 1993 Sep;52(5):507-15 [8103086.001]
  • [Cites] Neuro Oncol. 1999 Apr;1(2):124-37 [11550308.001]
  • [Cites] Hum Pathol. 1999 Nov;30(11):1284-90 [10571506.001]
  • [Cites] Int J Oncol. 1998 Nov;13(5):963-6 [9772286.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Jul;63(7):700-7 [15290895.001]
  • [Cites] Oncology. 2004;66(5):395-403 [15331927.001]
  • [Cites] Cancer Res. 1992 Aug 15;52(16):4550-3 [1322795.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):115-9 [10665922.001]
  • [Cites] Brain Pathol. 2003 Oct;13(4):507-18 [14655756.001]
  • [Cites] Acta Neurochir Suppl. 2003;88:105-11 [14531568.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Aug;28(4):325-33 [12175345.001]
  • [Cites] Int J Oncol. 2002 Sep;21(3):667-74 [12168116.001]
  • [Cites] Acta Neuropathol. 1996 Jul;92(1):70-4 [8811128.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):150-3 [8548755.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Mar;12(3):165-72 [7536455.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2124-8 [11280776.001]
  • [Cites] Oncol Rep. 2001 Sep-Oct;8(5):1039-43 [11496313.001]
  • [Cites] Oncologist. 2004;9(2):197-206 [15047924.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7404-7 [11606370.001]
  • [Cites] Clin Cancer Res. 1999 May;5(5):985-90 [10353730.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3369-75 [12960124.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3620-4 [14506149.001]
  • [Cites] Brain Pathol. 2000 Apr;10 (2):249-59 [10764044.001]
  • [Cites] Neuro Oncol. 1999 Jan;1(1):44-51 [11550301.001]
  • [Cites] Brain Pathol. 2004 Apr;14(2):131-6 [15193025.001]
  • [Cites] Zhonghua Yu Fang Yi Xue Za Zhi. 2002 Dec;36(7):517-8 [12411158.001]
  • [Cites] J Neurooncol. 2003 Oct;65(1):37-48 [14649884.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):228-33 [14734474.001]
  • [Cites] N Engl J Med. 2002 Feb 7;346(6):420-7 [11832530.001]
  • [Cites] Cancer. 2004 Sep 1;101(5):1036-42 [15329913.001]
  • [Cites] Neurosurgery. 1999 Dec;45(6):1442-53 [10598712.001]
  • (PMID = 16195804.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 52
  •  go-up   go-down


83. Stasiukyniene V, Pilvinis V, Reingardiene D, Janauskaite L: [Epileptic seizures in critically ill patients]. Medicina (Kaunas); 2009;45(6):501-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the intensive care settings, seizures and status epilepticus are a common neurologic complication, which is attributable to primary neurologic pathology (stroke, hemorrhage, tumor, central nervous system infection, head trauma) or secondary to critical illness (anoxic brain damage, intoxications, metabolic abnormalities) and clinical management.
  • [MeSH-minor] Adolescent. Adult. Anticonvulsants / therapeutic use. Epilepsy, Generalized / chemically induced. Epilepsy, Generalized / complications. Epilepsy, Generalized / diagnosis. Epilepsy, Generalized / drug therapy. Epilepsy, Generalized / mortality. Epilepsy, Generalized / physiopathology. Epilepsy, Generalized / therapy. Humans. Middle Aged. Prognosis. Randomized Controlled Trials as Topic. Time Factors. Transcranial Magnetic Stimulation

  • Genetic Alliance. consumer health - Seizures.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19605972.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] lit
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Lithuania
  • [Chemical-registry-number] 0 / Anticonvulsants
  • [Number-of-references] 41
  •  go-up   go-down


84. Neuwelt EA, Várallyay CG, Manninger S, Solymosi D, Haluska M, Hunt MA, Nesbit G, Stevens A, Jerosch-Herold M, Jacobs PM, Hoffman JM: The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study. Neurosurgery; 2007 Apr;60(4):601-11; discussion 611-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study.
  • OBJECTIVE: Ferumoxytol, an iron oxide nanoparticle that targets phagocytic cells, can be used in magnetic resonance imaging of malignant brain tumors and can be administered as a bolus, allowing dynamic imaging.
  • METHODS: Twelve patients with malignant brain tumors underwent serial magnetic resonance imaging multiple times up to 72 hours after ferumoxytol injection at both 1.5 and 3-T.
  • Maximal ferumoxytol enhancement intensity was at 24 to 28 hours after administration, and the enhancing volume subsequently expanded with time into a non-gadolinium-enhancing, high T2-weighted signal region of tumor-infiltrated brain.
  • CONCLUSION: Our most important finding was that gadolinium leaks out of blood vessels early after injection, whereas ferumoxytol stays intravascular in the "early" phase, thereby increasing the accuracy of tumor perfusion assessment.
  • As a magnetic resonance imaging contrast agent, ferumoxytol visualizes brain tumors at all field strengths evaluated, with delayed enhancement peaking at 24 to 28 hours after administration.
  • [MeSH-major] Brain Neoplasms / diagnosis. Ferrosoferric Oxide / administration & dosage. Gadolinium DTPA / administration & dosage. Image Enhancement / methods. Magnetic Resonance Angiography / methods
  • [MeSH-minor] Adult. Aged. Contrast Media / administration & dosage. Feasibility Studies. Female. Humans. Male. Middle Aged. Nanoparticles. Perfusion / methods. Pilot Projects

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • SciCrunch. DrugBank: Data: Chemical .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17415196.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 84F6U3J2R6 / gadodiamide; K2I13DR72L / Gadolinium DTPA; XM0M87F357 / Ferrosoferric Oxide
  •  go-up   go-down


85. Parlato R, Kreiner G, Erdmann G, Rieker C, Stotz S, Savenkova E, Berger S, Grummt I, Schütz G: Activation of an endogenous suicide response after perturbation of rRNA synthesis leads to neurodegeneration in mice. J Neurosci; 2008 Nov 26;28(48):12759-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The transcription factor TIF-IA plays a central role in mammalian rRNA synthesis, regulating the transcriptional activity of RNA polymerase I.
  • To investigate the consequences of nucleolar perturbation in the nervous system, we have chosen to specifically ablate the gene encoding the transcription factor TIF-IA in two different contexts: neural progenitors and hippocampal neurons.
  • Nondividing cells of the adult hippocampus are more refractory to loss of rRNA transcription and face a protracted degeneration.
  • [MeSH-minor] Animals. Cell Nucleolus / genetics. Cell Nucleolus / metabolism. Cell Nucleolus / pathology. Mice. Mice, Knockout. Mice, Transgenic. Neurogenesis / genetics. Neuronal Plasticity / genetics. Stem Cells / metabolism. Stem Cells / pathology. Transcription, Genetic / genetics. Tumor Suppressor Protein p53 / metabolism

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19036968.001).
  • [ISSN] 1529-2401
  • [Journal-full-title] The Journal of neuroscience : the official journal of the Society for Neuroscience
  • [ISO-abbreviation] J. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pol1 Transcription Initiation Complex Proteins; 0 / RNA, Ribosomal; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


86. Lee Y, Kim JH, Kim E, Park SH, Yim YJ, Sohn CH, Chang KH: Tumor-mimicking primary angiitis of the central nervous system: initial and follow-up MR features. Neuroradiology; 2009 Oct;51(10):651-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-mimicking primary angiitis of the central nervous system: initial and follow-up MR features.
  • INTRODUCTION: Primary angiitis of the central nervous system (PACNS) is an extremely rare vasculitis of unknown etiology.
  • The purpose of this study was to describe the initial and follow-up magnetic resonance (MR) imaging features of the tumor-mimicking PACNS.
  • METHODS: We retrospectively reviewed a total of 21 initial and follow-up brain MR images obtained in four patients with biopsy-proven PACNS mimicking brain tumor on MR images during the periods from 1 to 8.1 years.
  • CONCLUSION: Tumor-mimicking PACNS shows variable features on initial MR images but shows good responses to appropriate immunosuppressive therapy on follow-up MR images.
  • [MeSH-major] Brain / pathology. Vasculitis, Central Nervous System / pathology
  • [MeSH-minor] Adult. Brain Neoplasms / pathology. Cerebral Angiography. Diagnosis, Differential. Diffusion Magnetic Resonance Imaging. Female. Follow-Up Studies. Humans. Immunosuppression. Immunosuppressive Agents / therapeutic use. Magnetic Resonance Angiography. Magnetic Resonance Spectroscopy. Male. Protons. Recurrence. Retrospective Studies. Time Factors. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2007 Oct;107(4):873-7 [17937238.001]
  • [Cites] Neurology. 1997 Dec;49(6):1696-9 [9409370.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Jan;27(1):192-9 [16418382.001]
  • [Cites] Ann Rheum Dis. 2008 Dec;67(12):1732-5 [18625623.001]
  • [Cites] J Neurol. 1984;231(1):38-42 [6716109.001]
  • [Cites] Neuroradiology. 2007 Jun;49(6):471-9 [17345075.001]
  • [Cites] Australas Radiol. 2003 Jun;47(2):127-34 [12780440.001]
  • [Cites] Neurology. 1995 Sep;45(9):1731-4 [7675235.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Jan;20(1):87-9 [9974061.001]
  • [Cites] Cleve Clin J Med. 1992 May-Jun;59(3):293-306 [1516217.001]
  • [Cites] Neuroradiology. 2001 Aug;43(8):599-607 [11548164.001]
  • [Cites] Ann Neurol. 2007 Nov;62(5):442-51 [17924545.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Mar;26(3):642-5 [15760879.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 Feb;15(2):317-30 [8192080.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Jan;20(1):75-85 [9974060.001]
  • [Cites] Arthritis Rheum. 2008 Feb;58(2):595-603 [18240248.001]
  • [Cites] Neurology. 1995 Aug;45(8):1462-5 [7644041.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Oct;23(9):1561-3 [12372748.001]
  • [Cites] Radiology. 1992 Jan;182(1):65-72 [1727311.001]
  • [Cites] Surg Neurol. 1989 Jan;31(1):49-53 [2645673.001]
  • [Cites] Hum Pathol. 1992 Feb;23(2):164-71 [1740300.001]
  • (PMID = 19529928.001).
  • [ISSN] 1432-1920
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Protons
  •  go-up   go-down


87. Capper D, Weissert S, Balss J, Habel A, Meyer J, Jäger D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H, Hartmann C, von Deimling A: Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol; 2010 Jan;20(1):245-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.
  • Here we investigate the capability of this antibody to differentiate wild type and mutated IDH1 protein in central nervous system (CNS) tumors by Western blot and immunohistochemistry.
  • In Western blot, anti-IDH1R132H mouse monoclonal antibody mIDH1R132H detected a specific band only in mutated tumors.
  • Immunohistochemistry of 345 primary brain tumors demonstrated a strong cytoplasmic and weaker nuclear staining in 122 cases.
  • Intriguing is the ability of mIDH1R132H to detect single infiltrating tumor cells.
  • The very high frequency and the distribution of this mutation among specific brain tumor entities allow the highly sensitive and specific discrimination of various tumors by immunohistochemistry, such as anaplastic astrocytoma from primary glioblastoma or diffuse astrocytoma World Health Organization (WHO) grade II from pilocytic astrocytoma or ependymoma.
  • Noteworthy is the discrimination of the infiltrating edge of tumors with IDH1 mutation from reactive gliosis.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / enzymology. Brain Neoplasms / genetics. Ependymoma / genetics. Glioma / enzymology. Glioma / genetics. Isocitrate Dehydrogenase / genetics. Isocitrate Dehydrogenase / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigen-Antibody Reactions. Blotting, Western. Child. Child, Preschool. Cloning, Molecular. DNA, Neoplasm / biosynthesis. DNA, Neoplasm / genetics. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Mutation / genetics. Mutation / physiology. Protein Biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19903171.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42. / IDH1 protein, human
  •  go-up   go-down


88. Hankins GR, Sasaki T, Lieu AS, Saulle D, Karimi K, Li JZ, Helm GA: Identification of the deleted in liver cancer 1 gene, DLC1, as a candidate meningioma tumor suppressor. Neurosurgery; 2008 Oct;63(4):771-80; discussion 780-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of the deleted in liver cancer 1 gene, DLC1, as a candidate meningioma tumor suppressor.
  • OBJECTIVE: Meningiomas are the second most common primary tumors of the central nervous system.
  • Down-regulation of a differentially expressed tumor suppressor gene, deleted in liver cancer 1 (DLC1), was verified by quantitative real-time reverse transcription-polymerase chain reaction and immunohistochemical staining.
  • CONCLUSION: The results suggest that DLC1 may function as a tumor suppressor gene in meningiomas.
  • Furthermore, DLC1 promoter methylation does not appear to be responsible for the decreased DLC1 expression in these tumors.
  • [MeSH-major] Meningioma / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adenoviridae / genetics. Adult. Aged. Aged, 80 and over. Cell Proliferation. DNA Methylation / genetics. Down-Regulation. Dura Mater / metabolism. Female. GTPase-Activating Proteins. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Gene Transfer Techniques. Genetic Vectors / genetics. Humans. Male. Middle Aged. Promoter Regions, Genetic / genetics


89. Caroli E, Salvati M, Ferrante L: Tumor-like multiple sclerosis: report of four cases and literature review. Tumori; 2006 Nov-Dec;92(6):559-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-like multiple sclerosis: report of four cases and literature review.
  • This non-neoplastic demyelinating process of the central nervous system generally does not produce focal space-occupying lesions associated with ring enhancement.
  • However, atypical appearance of demyelinating lesions simulating a brain tumor is a possible well-known phenomenon.
  • METHODS: We present our experience with 4 cases of multiple sclerosis indistinguishable clinically and neuroradiologically from a cerebral tumor.
  • CONCLUSIONS: The presented cases demonstrate the importance of considering a demyelinating disease in the differential diagnosis of a tumor-like brain lesion.
  • [MeSH-major] Brain Neoplasms / diagnosis. Multiple Sclerosis / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed


90. Park YS, Ahn JY, Kim DS, Kim TS, Kim SH: Late development of craniopharyngioma following surgery for Rathke's cleft cyst. Clin Neuropathol; 2009 May-Jun;28(3):177-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 34 months after the initial surgery, the patient revisited our hospital for a rapidly aggravating visual disturbance and underwent neuroendoscopic biopsy and tumor removal via a bifrontal craniotomy.
  • Histologically, the tumor was shown to be an adamantinomatous CP.
  • [MeSH-major] Central Nervous System Cysts / pathology. Craniopharyngioma / pathology. Neoplasms, Second Primary / pathology. Pituitary Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male. Neurosurgical Procedures. beta Catenin / metabolism

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19537134.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / beta Catenin
  •  go-up   go-down


91. Kashyap R, Ryan C, Sharma R, Maloo MK, Safadjou S, Graham M, Tretheway D, Jain A, Orloff M: Liver grafts from donors with central nervous system tumors: a single-center perspective. Liver Transpl; 2009 Oct;15(10):1204-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver grafts from donors with central nervous system tumors: a single-center perspective.
  • However, it has become a common practice to accept organs from donors that have low-grade tumors or tumors with low metastatic potential.
  • The aim of this study was to analyze our experience with the use of liver grafts from donors with central nervous system (CNS) tumors.
  • A retrospective review of 1173 liver transplants performed between 1992 and 2006 identified 42 donors diagnosed with a CNS tumor.
  • Thirty-two tumors were malignant, and 10 tumors were benign.
  • Twenty (47.6%) of the CNS tumors were glioblastoma multiforme (astrocytoma grade IV), 11 (26.2%) were other astrocytomas, and 1 (2.4%) was an anaplastic ependymoma.
  • Twenty (62.5%) neoplasms were grade IV tumors, 8 (25%) were grade II tumors, and 4 (12.5%) were grade III tumors.
  • The rate of recurrence for the entire group was 2.4% (all CNS tumors).
  • There was no difference in survival between recipients of grafts from donors with CNS tumors and recipients of grafts from donors without CNS tumors (1 year: 82% versus 83.3%, P = not significant; 3 years: 77.4% versus 72%, P = not significant).
  • In conclusion, in our experience, despite violation of the blood-brain barrier and high-grade CNS tumors, recurrence was uncommon.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Liver Diseases / therapy. Liver Transplantation / methods. Tissue and Organ Procurement / methods
  • [MeSH-minor] Adult. Blood-Brain Barrier. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Time Factors. Tissue Donors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 AASLD
  • [CommentIn] Liver Transpl. 2010 Jul;16(7):916 [20583090.001]
  • [CommentIn] Liver Transpl. 2010 Jul;16(7):914-5 [20583288.001]
  • (PMID = 19790151.001).
  • [ISSN] 1527-6473
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Yoshimi A, Taoka K, Nakasone H, Iijima K, Kida M, Iki S, Urabe A, Usuki K: [Superior sagittal sinus thrombosis during remission induction therapy for acute lymphoblastic leukemia]. Rinsho Ketsueki; 2006 Dec;47(12):1533-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Superior sagittal sinus thrombosis (SSST) has been reported to be caused by coagulopathy following oral contraceptive therapy, DIC, infection around the sinus, compression from a tumor, infiltration of tumor, and an inherited deficiency of proteins C and S, but SSST associated with hematological malignancies and L-asparaginase (L-Asp) therapy is rare.
  • We report a case of an adult patient with acute lymphoblastic leukemia (ALL) who developed SSST during the remission induction therapy.
  • A 25-year-old man was admitted with left facial nerve palsy and, following bone marrow aspiration and lumbar puncture, he was diagnosed as having T-ALL with CNS involvement.
  • Lymphoid malignancy (ALL in particular), the use of L-Asp, CNS involvement, and intrathecal chemotherapy might be risk factors for the occurrence SSST.
  • When a patient with those factors develops any neurological symptoms, we should pay attention to the occurrence of SSST, as well as stroke or CNS involvement, though SSST is rare.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Asparaginase / administration & dosage. Asparaginase / adverse effects. Central Nervous System Neoplasms / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Sagittal Sinus Thrombosis / etiology
  • [MeSH-minor] Adult. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Cytarabine / adverse effects. Doxorubicin / administration & dosage. Facial Paralysis / etiology. Humans. Injections, Spinal. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Mitoxantrone / administration & dosage. Prednisolone / administration & dosage. Remission Induction. Risk Factors. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Thrombosis.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17233472.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; EC 3.5.1.1 / Asparaginase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


93. Omalu BI, Nnebe-Agumadu UH: Occurrence of anaplastic oligodendroglioma in a patient with Williams syndrome: a case report with analysis of mutational profile of tumor. Niger J Clin Pract; 2009 Jun;12(2):200-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occurrence of anaplastic oligodendroglioma in a patient with Williams syndrome: a case report with analysis of mutational profile of tumor.
  • Chromosome 7q contains putative tumor suppressor genes and is one of the chromosomes that are frequently involved in chromosomal aberrations in human malignancies.
  • A paucity of tumors (three) has been reported in the literature to occur in patients with Williams syndrome.
  • We draw attention to this apparently rare or possibly under-reported occurrence of tumors in patients with Williams syndrome and suggest that Central Nervous System [CNS] tumors be considered as differential diagnoses in such patients when they present with unanticipated neurologic symptoms that are not attributable to those commonly associated with Williams syndrome.
  • [MeSH-major] Brain Neoplasms / epidemiology. Oligodendroglioma / epidemiology. Parietal Lobe. Williams Syndrome / epidemiology
  • [MeSH-minor] Adult. Comorbidity. DNA Mutational Analysis. Humans. Loss of Heterozygosity. Male. Neurologic Examination


94. Häyry V, Tynninen O, Haapasalo HK, Wölfer J, Paulus W, Hasselblatt M, Sariola H, Paetau A, Sarna S, Niemelä M, Wartiovaara K, Nupponen NN: Stem cell protein BMI-1 is an independent marker for poor prognosis in oligodendroglial tumours. Neuropathol Appl Neurobiol; 2008 Oct;34(5):555-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: The polycomb factor BMI-1 has recently been implicated in tumorigenesis of the central nervous system in several experimental animal models.
  • METHODS: Tumour samples were collected from 305 adult patients treated for primary grades 2-4 gliomas between 1980 and 2006 in Finland and Germany.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Glioma / metabolism. Nuclear Proteins / biosynthesis. Proto-Oncogene Proteins / biosynthesis. Repressor Proteins / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Female. Gene Expression. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Polycomb Repressive Complex 1. Proto-Oncogene Proteins c-mdm2 / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18346113.001).
  • [ISSN] 1365-2990
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BMI1 protein, human; 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / Repressor Proteins; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Polycomb Repressive Complex 1; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


95. Giovinale M, Fonnesu C, Soriano A, Cerquaglia C, Curigliano V, Verrecchia E, De Socio G, Gasbarrini G, Manna R: Atypical sarcoidosis: case reports and review of the literature. Eur Rev Med Pharmacol Sci; 2009 Mar;13 Suppl 1:37-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extrapulmonary involvement is common and all organs can be involved (especially lymph nodes, eyes, joints, central nervous system) but it is rare to find an isolated extrapulmonary disease (less than 10% of patients).
  • Since she had a familiar history of colon cancer, abdominal US scan, abdominal CT scan and MRI were performed and showed inter-aorto-caval lymphadenopathies and discreet multiple bilobar hepatic and splenic substitutive lesions, with no signs of primary tumor.
  • Upper and lower GI endoscopy, full gynecological workup, complete set of tumor markers, bone marrow biopsy were performed.
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Tomography, X-Ray Computed


96. Corniola RS, Tassabehji NM, Hare J, Sharma G, Levenson CW: Zinc deficiency impairs neuronal precursor cell proliferation and induces apoptosis via p53-mediated mechanisms. Brain Res; 2008 Oct 27;1237:52-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The potential importance of stem cells in the adult central nervous system (CNS) that cannot only divide, but also participate in neurogenesis, is now widely appreciated.
  • While we know that the trace element zinc is needed for brain development, the role of this essential nutrient in adult stem cell proliferation and neurogenesis has not been investigated.
  • Adult male rats fed a zinc-restricted diet had approximately 50% fewer Ki67-positive stem cells in the subgranular zone (SGZ) and granular cell layer of the dentate gyrus compared to both zinc-adequate and pair-fed controls (p<0.05).
  • [MeSH-major] Apoptosis / physiology. Cell Proliferation. Neurons / physiology. Stem Cells / physiology. Tumor Suppressor Protein p53 / metabolism. Zinc / deficiency

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18778698.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Chelating Agents; 0 / Ethylenediamines; 0 / Ki-67 Antigen; 0 / Reactive Oxygen Species; 0 / Tumor Suppressor Protein p53; 16858-02-9 / N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine; EC 3.4.22.- / Caspase 3; EC 4.2.1.11 / Phosphopyruvate Hydratase; G34N38R2N1 / Bromodeoxyuridine; J41CSQ7QDS / Zinc
  •  go-up   go-down


97. Ijiri K, Hida K, Yano S, Iwasaki Y: Ventrally located cervical intramedullary cavernous angioma: selection of posterior and anterior approaches: case report. Neurol Med Chir (Tokyo); 2009 Oct;49(10):474-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Laminectomy (C2-C7) was performed, followed by posterior midline myelotomy and removal of the intramedullary hematoma and the tumor.
  • Complete removal of the tumor was attained and salvage surgery was performed.
  • [MeSH-major] Hemangioma, Cavernous, Central Nervous System / diagnosis. Hemangioma, Cavernous, Central Nervous System / surgery. Laminectomy / methods. Spinal Cord / surgery. Spinal Cord Diseases / diagnosis. Spinal Cord Diseases / surgery
  • [MeSH-minor] Adult. Arm / pathology. Arm / physiopathology. Blood Vessels / pathology. Cervical Vertebrae / anatomy & histology. Cervical Vertebrae / surgery. Disease Progression. Female. Hematoma / etiology. Hematoma / pathology. Hematoma / surgery. Humans. Intraoperative Complications / etiology. Intraoperative Complications / prevention & control. Magnetic Resonance Imaging. Methylmethacrylates. Neurosurgical Procedures. Paresis / etiology. Paresis / physiopathology. Postoperative Hemorrhage / etiology. Postoperative Hemorrhage / prevention & control. Postoperative Hemorrhage / surgery. Reoperation. Spinal Fusion. Treatment Outcome. Vascular Surgical Procedures / methods

  • Genetic Alliance. consumer health - Angioma.
  • MedlinePlus Health Information. consumer health - Spinal Cord Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19855146.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Methylmethacrylates; 0 / vertebroplastic
  •  go-up   go-down


98. Khan MK, Hunter GK, Vogelbaum M, Suh JH, Chao ST: Evidence-based adjuvant therapy for gliomas: current concepts and newer developments. Indian J Cancer; 2009 Apr-Jun;46(2):96-107
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 18,820 new cases of primary central nervous system (CNS) tumors diagnosed annually in the United States, gliomas account for over 60% with 30-40% of them being glioblastoma multiforme (GBM), 10% being anaplastic astrocytoma (AA), and 10% being low grade gliomas (LGGs).
  • This is in contrast to one study from West Bengal, India, in which only 7.9% of the brain tumors were GBMs, while 46.8% were astrocytomas.
  • Of all adult primary CNS tumors, GBM is the most common and the most malignant with about 7,000 to 8,000 new cases annually in the United States.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Chemotherapy, Adjuvant. Evidence-Based Medicine. Glioma / therapy. Radiotherapy, Adjuvant

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19346643.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 64
  •  go-up   go-down


99. Tohmé A, Koussa S, Haddad-Zébouni S, El-Rassi B, Ghayad E: [Neurological manifestations of Behcet's disease: 22 cases among 170 patients]. Presse Med; 2009 May;38(5):701-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Central nervous system involvement was found in 21 patients and peripheral nervous system involvement in one.
  • Meningoencephalitis and/or transverse myelitis were found in 57% (12/21) of cases (in association with brainstem syndrome in 2 of these cases), brainstem syndrome without meningoencephalitis in 5 cases, tumor-like syndrome in 2 cases, repetitive ischemic attacks in 1 case and cerebral venous thrombosis in one.
  • MRI, performed in 9 patients, was abnormal in 6 and showed abnormal signals distributed over the brainstem and the thalamus in 4, a tumor-like lesion and thrombosis of the left lateral sinus one each.
  • CONCLUSION: Within central neurological involvement in Behçet's disease, we can individualize 4 clinical aspects: meningoencephalitis (and/or myelitis), brainstem syndrome, tumor-like features and cerebral venous thrombosis.
  • [MeSH-major] Behcet Syndrome / complications. Central Nervous System Diseases / etiology. Peripheral Nervous System Diseases / etiology
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Brain / pathology. Female. Humans. Immunosuppressive Agents / therapeutic use. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies. Sex Factors

  • Genetic Alliance. consumer health - Behcet's Disease.
  • MedlinePlus Health Information. consumer health - Behcet's Syndrome.
  • MedlinePlus Health Information. consumer health - Peripheral Nerve Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19062244.001).
  • [ISSN] 2213-0276
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Immunosuppressive Agents
  •  go-up   go-down


100. Brown M, Schrot R, Bauer K, Dodge J: Incidence of first primary central nervous system tumors in California, 2001-2005: children, adolescents and teens. J Neurooncol; 2009 Sep;94(2):263-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of first primary central nervous system tumors in California, 2001-2005: children, adolescents and teens.
  • This study used data from the California Cancer Registry to comprehensively examine first primary central nervous system tumors (PCNST) by the International Classification of Childhood Cancers (ICCC) diagnostic groups and to compare their incidence by age groups, sex, race/ethnicity, socioeconomic status and tumor behavior.
  • [MeSH-major] Central Nervous System Neoplasms / epidemiology. Glioblastoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. California / epidemiology. Child. Child, Preschool. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Time Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19340399.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCCDPHP CDC HHS / DP / 1U58DP00807-01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down






Advertisement